

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07747 A1

(51) International Patent Classification⁷: A61K 38/00, C12N 9/12, C12Q 1/48

(21) International Application Number: PCT/US01/22347

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/219,244 18 July 2000 (18.07.2000) US

(71) Applicant (for all designated States except US): JOSLIN
DIABETES CENTER, INC. [US/US]; One Joslin Place,
Boston, MA 02115 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KING, George, Liang
[US/US]; 101 Sentre Street, Dover, MA 02030 (US).

(74) Agents: MYERS, P., Louis et al.; Fish & Richardson P.C.,
225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

WO 02/07747 A1

(54) Title: METHODS OF MODULATING FIBROSIS

(57) Abstract: The invention features method fo modulating fibrosis and/or angiogenesis by inhibiting components of the VEGF signaling pathway. The methods are useful in the treatment of fibrotic and or angiogenesis related disorders.

METHODS OF MODULATING FIBROSIS

Related Applications

This application claims the benefit of U.S. Provisional application No. 60/219,244, filed on July 18, 2000, the contents of which are incorporated herein by reference in their entirety.

Federally Sponsored Research Or Development

The U.S. Government may have certain rights in this invention pursuant to Grant No. EY5110 awarded by the National Institutes of Health to George L. King.

Background

Angiogenesis and fibrosis are key components in development, growth, wound healing, and regeneration (Klagsbrun & D'Amore, (1991) *Annu. Rev. Physiol.* 53, 217-239). In addition, these processes commonly occur together in many disease states where neovascularization is believed to initiate the pathological cascade, including proliferative diabetic retinopathy (Aiello et al. (1998) *Diabetes Care* 21, 143-156), rheumatoid arthritis (Firestein (1999) *J. Clin. Invest.* 103, 3-4), and age-related macular degeneration (Lopez et al. (1996) *Invest. Ophthalmol. & Visual Sci.* 37, 855-868).

Vascular endothelial growth factor (VEGF) is expressed as a family of peptides of 121, 145, 165, 189, and 206 amino acid residues. Its expression is induced by hypoxia and is essential in the vasculogenesis process during development. Several receptors have been shown to mediate the action of VEGF, and most of them belong to the tyrosine kinase receptor family (Petrova et al. (1999) *Exp. Cell Res.* 253, 117-130). Upon the binding of VEGF to its receptors, multiple signaling cascades are activated, including the tyrosine phosphorylation of phospholipase Cy, elevation of intracellular calcium and diacylglycerol, activation of protein kinase C (PKC), and extracellular signal-regulated kinase (MAPK/ERK) for endothelial cell proliferation. In addition, VEGF also stimulates activation of phosphatidylinositol (PI) 3-kinase leading to Akt/PKB activation and possibly enhancing endothelial cell survival.

Connective tissue growth factor (CTGF) is a potent and ubiquitously expressed growth factor that has been shown to play a unique role in fibroblast proliferation, cell adhesion, and

the stimulation of extracellular matrix production (Frazier et al. (1996) *J. Invest. Dermatol.* 107, 404-411; Kireeva et al. (1997) *Exp. Cell Res.* 233, 63-77). The 38-kDa protein was originally identified in conditioned medium from human umbilical vein endothelial cells, and the expression was shown to be selectively stimulated by transforming growth factor- β (TGF- β) in cultured fibroblasts. Due to its mitogenic action on fibroblasts and its ability to induce the expression of the extracellular matrix molecules, collagen type I, fibronectin, and integrin $\alpha 5$, CTGF is supposed to play an important role in connective tissue cell proliferation and extracellular matrix deposition as one of the mediators of TGF- β . CTGF also seems to be an important player in the pathogenesis of various fibrotic disorders, since it was shown to be overexpressed in scleroderma, keloids, and other fibrotic skin disorders (Igarashi et al. (1996) *J. Invest. Dermatol.* 106, 729-733), as well as in stromal rich mammary tumors, and in advanced atherosclerotic lesions. Recently, the integrin $\alpha 5\beta 3$ has been reported to serve as a receptor on endothelial cells for CTGF-mediated endothelial cell adhesion, migration, and angiogenesis (Babic et al. (1999) *Mol. Cell. Biol.* 19, 2958-2966).

Besides TGF- β , the expression of CTGF is reported to be regulated by dexamethasone in BALB/c 3T3 cells, high glucose in human mesangial cells, kinin in human embryonic fibroblasts, factor VIIa, and thrombin in WI-38 fibroblasts, tumor necrosis factor α in human skin fibroblast, and cAMP in bovine endothelial cells (Dammeier et al. (1998) *J. Biol. Chem.* 273, 18185-18190; Murphy et al. (1999) *J. Biol. Chem.* 274, 5830-5834; Ricupero et al. (2000) *J. Biol. Chem.* 275, 12475-12480; Pendurthi et al. (2000) *J. Biol. Chem.* 275, 14632-14641; Abraham et al. (2000) *J. Biol. Chem.* 275, 15220-15225; Boes et al. (1999) *Endocrinology* 140, 1575-1580).

Summary

The invention is based, in part, on the discovery that VEGF can regulate connective tissue growth factor (CTGF), e.g., through the PI3 Kinase-Akt pathway. CTGF is a potent diffusible growth factor which regulates extracellular matrix deposition and connective tissue cell proliferation. CTGF is a potent activator of fibrosis, angiogenesis, and extracellular matrix production. Modulation of the levels of CTGF via the VEGF pathway, e.g., by modulation of a VEGF activity, e.g., a VEGF signaling activity, e.g., a VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt 4, neuropilin-1 (NP-1), tie, or tie2 activity;

modulation of PI3-kinase; or modulation of Akt can thereby stimulate or alternatively reduce fibrosis and/or angiogenesis. Accordingly, one aspect of the invention features methods of modulating fibrosis. Another aspect features methods of modulating angiogenesis.

In one aspect, the invention features a method of decreasing fibrosis in a tissue, e.g., a skin, lung, retinal, renal, cardiac, or liver tissue of a subject, e.g., a human or non-human animal, by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity. In a preferred embodiment, the method includes identifying a subject in need of decreased fibrosis, e.g., a subject having a fibrotic disorder, e.g., a disorder described herein.

In a preferred embodiment, VEGF signaling is decreased by administering an agent that inhibits a component of the VEGF signal transduction pathway, e.g., an agent that decreases VEGF activity, decreases VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt4, NP-1, tie, or tie2 activity; decreases PI3-kinase activity; decreases an Akt activity; decreases an Erk activity.

In a preferred embodiment, KDR, Flt-4, Flt-1 or neuropilin activity is decreased.

In a preferred embodiment, the subject has a disorder related to unwanted or excessive fibrosis. In some embodiments, fibrosis is exhibited in, e.g., skin, liver, kidney, cardiac, or lung tissue. The disorder can be caused by scarring, e.g., keloid formation. Examples of other disorders related to unwanted or excessive fibrosis include, but are not limited to, scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis, e.g., diffuse interstitial pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; a disease of the kidney, e.g., glomerular sclerosis, renal tubulointerstitial fibrosis, or progressive renal disease; atherosclerotic plaques, e.g., restenosis; inflammatory bowel disease; Crohn's disease; arthritic joints, e.g., rheumatoid arthritis; cancer, e.g., invasive breast carcinoma, stromal rich mammary tumors, dermatofibromas, angiolioma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture; macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal

fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments; or macular degeneration, e.g., age-related macular degeneration;

The method includes administering an agent which decreases CTGF activity or expression. In a preferred embodiment, the agent is an agent described herein that decreases a VEGF signaling activity.

In a preferred embodiment, CTGF activity or expression is decreased in an endothelial cell.

In a preferred embodiment, CTGF activity or expression is decreased in a pericyte.

An agent which decreases CTGF activity can be one or more of: an agent which decreases the level or activity of VEGF, e.g., an agent which inhibits VEGF interaction with a VEGF receptor (VEGFR), e.g., flt4, fltl, NP-1 tie, tie-2, and/or KDR/flk1; an agent which inhibits VEGF receptor activation; an agent which disrupts a VEGF-VEGFR complex; an agent which inhibits PI3 Kinase activity; an agent that inhibits VEGFR binding to p85, the catalytic subunit of PI3 kinase; an agent which inhibits AKT kinase activity.

In a preferred embodiment, VEGF is inhibited. VEGF can be inhibited by administering an agent which inhibits VEGF gene expression, protein production levels and/or activity. An agent which inhibits VEGF can be one or more of: a VEGF binding protein, e.g., a soluble VEGF binding protein, e.g., the ectodomain of a VEGF-receptor; an antibody that specifically binds to the VEGF protein, e.g., an antibody that disrupts VEGF's ability to bind to its natural cellular target, e.g., disrupts VEGF's ability to bind to a VEGF receptor, e.g., Fltl (VEGFR1), Flk1/KDR (VEGFR2), NP-1, tie, tie-2, or Flt4 (VEGFR3); an antibody that disrupts the ability of a VEGF receptor to bind to VEGF; an antibody or small molecule which disrupts a complex formed by VEGF and its receptor; a mutated inactive VEGF or fragment which binds to a VEGF receptor but does not activate the receptor; a VEGF nucleic acid molecule which can bind to a cellular VEGF nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF ribozyme; an agent which decreases VEGF gene expression, e.g., a small molecule which binds the promoter of VEGF. In another preferred embodiment, VEGF is inhibited by decreasing the level of expression of an endogenous VEGF gene, e.g., by decreasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene can be decreased by: altering the regulatory sequences of the endogenous VEGF gene, e.g., by the

addition of a negative regulatory sequence (such as a DNA-biding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, the antibody which binds VEGF is a monoclonal antibody, e.g., a humanized chimeric or human monoclonal antibody.

In a preferred embodiment, VEGF interaction with its receptor is inhibited. An agent which inhibits a VEGF receptor, e.g., Fltl (VEGFR1), Flkl/KDR (VEGFR2), neuropilin-1, tie, tie-2, or Flt4 (VEGFR3), can be one or more of: a VEGF receptor nucleic acid molecule which can bind to a cellular VEGF receptor nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF receptor ribozyme; an agent which decreases VEGF receptor gene expression, e.g., a small molecule which binds the promoter of a VEGF receptor. In another preferred embodiment, a VEGF receptor is inhibited by decreasing the level of expression of an endogenous VEGF receptor gene, e.g., by decreasing transcription of an VEGF receptor gene. In a preferred embodiment, transcription of a VEGF receptor gene can be decreased by: altering the regulatory sequences of an endogenous VEGF receptor gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-biding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA binding site for a transcriptional activator); as well as agents described above.

In a preferred embodiment, PI3 kinase is inhibited. An agent which inhibits PI3-kinase activity can be one or more of: a small molecule which inhibits PI3-kinase activity, e.g., LY294002; a protein or peptide that inhibits PI3 kinase activity, e.g., a PI3 kinase binding protein which binds to PI3-kinase but does not activate the enzyme, or a dominant negative form of p85; an antibody that specifically binds to the PI3-kinase protein, e.g., an antibody that disrupts PI3-kinase's catalytic activity or an antibody that disrupts the ability of cellular receptors to activate PI3-kinase; a PI3 kinase nucleic acid molecule which can bind to a cellular PI3 kinase nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or PI3-kinase ribozyme; an agent which decreases PI3-kinase gene expression, e.g., a small molecule which binds the promoter of PI3-kinase. In another preferred embodiment, PI3-kinase is inhibited by decreasing the level of expression of an endogenous PI3-kinase gene, e.g.,

by decreasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene can be decreased by: altering the regulatory sequences of the endogenous PI3-kinase gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-biding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, PI3-kinase activity is inhibited by a specific small molecule inhibitor, e.g., wortmannin or LY294002.

In another preferred embodiment, AKT kinase is inhibited. An agent which inhibits AKT kinase activity can be one or more of: a specific small molecule which inhibits AKT activity; an AKT binding protein which binds to AKT but does not activate the enzyme; an antibody that specifically binds to the AKT protein, e.g., an antibody that disrupts AKT's catalytic activity or an antibody that disrupts the ability of the AKT PH domain to sense activating second messengers, e.g., phosphoinositides; a mutated inactive AKT or fragment which binds to a AKT receptor but does not activate the receptor; an AKT nucleic acid molecule which can bind to a cellular AKT nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or AKT ribozyme; an agent which decreases AKT gene expression, e.g., a small molecule which binds the promoter of AKT. In another preferred embodiment, AKT is inhibited by decreasing the level of expression of an endogenous AKT gene, e.g., by decreasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene can be decreased by: altering the regulatory sequences of the endogenous AKT gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-biding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

In one embodiment, increasing a PKC activity, e.g., a PKC α , PKC β 1, PKC β 2, or PKC γ activity, can inhibit PI3 kinase or Akt, thus decreasing CTGF expression or activity. The agent which increases the level of PKC activity can be one or more of the following: a small molecule which stimulates PKC activity, e.g., PMA; a PKC polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof; an agent which increases PKC nucleic acid expression; e.g., a small molecule which binds to the promoter region of PKC. In a preferred embodiment, PKC levels are

increased by administering, e.g., introducing, a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PKC coding region; a promoter sequence, e.g., a promoter sequence from a PKC gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a PKC gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PKC gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PKC protein is increased by increasing the level of expression of an endogenous PKC gene, e.g., by increasing transcription of the PKC gene. In a preferred embodiment, transcription of the PKC gene is increased by: altering the regulatory sequence of the endogenous PKC gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PKC gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is inhibited. An agent which inhibits Erk kinase activity can be one or more of: a specific small molecule which inhibits Erk activity; a Erk binding protein which binds to Erk but does not activate the enzyme; an antibody that specifically binds to the Erk protein, e.g., an antibody that disrupts Erk's catalytic activity; a mutated inactive Erk or fragment which binds to a Erk receptor but does not activate the receptor; a Erk nucleic acid molecule which can bind to a cellular Erk nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or Erk ribozyme; an agent which decreases Erk gene expression, e.g., a small molecule which binds the promoter of Erk. In another preferred embodiment, Erk is inhibited by decreasing the level of expression of an endogenous Erk gene, e.g., by decreasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene can be decreased by: altering the regulatory sequences of the endogenous Erk gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-biding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

Another aspect of the invention features methods of reducing angiogenesis by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity by any of the methods described herein. In preferred embodiments, angiogenesis is reduced to, e.g., treat a disorder related to excessive angiogenesis, e.g., tumor growth, tumor metastasis, arthritis, retinal neovascular disease, and retinal ischemia. The method includes administering an agent which decreases CTGF transcription or activity by inhibiting a component of the VEGF signaling pathway, e.g., by any of the agents mentioned above.

Another aspect of the invention features methods of increasing fibrosis.

In a preferred embodiment, the invention features a method of treating disorders related to insufficient fibrosis. The disorder can be the result of an injury. The disorder can be due to a genetic deficiency, a second physiological disorder or disease, or an environmental insult. In a preferred embodiment, the disorder is a wound. In another preferred embodiment the disorder is a damaged organ, e.g., an organ undergoing regeneration. The method includes administering an agent which increases the level of CTGF transcription.

An agent which increases the level of CTGF transcription can be one or more of: an agent which increases the level or activity of VEGF, e.g., a transition metal ion, e.g., manganese, cobalt, nickel, or combinations thereof; an agent which activates the VEGF receptor; an agent which increases PI3 Kinase activity; an agent which increases AKT kinase activity.

In a preferred embodiment, VEGF is increased. An agent which increases the level of VEGF activity can be one or more of the following; a small molecule, e.g., a transition metal ion; a peptide or protein, e.g., a monoclonal antibody, which stabilizes or assists the binding of VEGF to a VEGF receptor; a VEGF polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF polypeptide or functional fragment or analog thereof; an agent which increases VEGF nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF. In a preferred embodiment, VEGF levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF polypeptide or

functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF coding region; a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3'UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF protein is increased by increasing the level of expression of an endogenous VEGF gene, e.g., by increasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene is increased by: altering the regulatory sequence of the endogenous VEGF gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF gene to be transcribed more efficiently.

In a preferred embodiment, the VEGF receptor activity is increased. An agent which increases the level of VEGF receptor activity can be one or more of the following: an agent which activates a VEGF receptor, e.g., a monoclonal antibody which activates the VEGF receptor, e.g., a monoclonal antibody which activates a VEGF receptor in the absence of VEGF; a VEGF receptor ligand polypeptide (e.g., VEGF or placenta growth factor (PIGF)), or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof; an agent which increase VEGF receptor nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF receptor. In a preferred embodiment, VEGF receptor levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF receptor coding region; a promoter sequence, e.g., a promoter sequence from a VEGF receptor gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF receptor

gene or from another gene, a 3'UTR, e.g., a 3'UTR from a VEGF receptor gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF receptor protein is increased by increasing the level of expression of an endogenous VEGF receptor gene, e.g., by increasing transcription of the VEGF receptor gene. In a preferred embodiment, transcription of the VEGF receptor gene is increased by: altering the regulatory sequence of the endogenous VEGF receptor gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF receptor gene to be transcribed more efficiently.

In a preferred embodiment, PI3-Kinase is increased. An agent which increases the level of PI3-kinase can be one or more of the following: a small molecule which activates PI3kinase; a PI3kinase polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PI3kinase polypeptide or functional fragment or analog thereof; an agent which increase PI3-kinase nucleic acid expression, e.g., a small molecule which binds to the promoter region of PI3 kinase. In a preferred embodiment, PI3-kinase levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a PI3-kinase polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PI3-kinase coding region; a promoter sequence, e.g., a promoter sequence from a PI3 kinase gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PI3kinase gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PI3-kinase gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PI3kinase protein is increased by increasing the level of expression of an endogenous PI3-kinase gene, e.g., by increasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene is increased by: altering the regulatory sequence of the endogenous PI3 kinase gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator);

the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PI3-kinase gene to be transcribed more efficiently.

In a preferred embodiment, AKT is increased. An agent which increases the level of AKT can be one or more of the following: a small molecule which activates AKT kinase activity, e.g., the phosphoinositide PIP₂; a polypeptide, e.g., insulin, which stimulates activation, e.g., phosphorylation, of AKT; a AKT polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof; an agent which increase AKT nucleic acid expression; e.g., a small molecule which binds to the promoter region of AKT. In a preferred embodiment, AKT levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a AKT coding region; a promoter sequence, e.g., a promoter sequence from a AKT gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a AKT gene or from another gene, a 3'UTR, e.g., a 3'UTR from a AKT gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of AKT protein is increased by increasing the level of expression of an endogenous AKT gene, e.g., by increasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene is increased by: altering the regulatory sequence of the endogenous AKT gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the AKT gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is increased. An agent which increases Erk kinase activity can be one or more of: a small molecule which activates Erk kinase activity; an Erk polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding

an Erk polypeptide or functional fragment or analog thereof; an agent which increases Erk nucleic acid expression; e.g., a small molecule which binds to the promoter region of Erk. In a preferred embodiment, Erk levels are increased by administering, e.g., introducing, a nucleotide sequence encoding an Erk polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: an Erk coding region; a promoter sequence, e.g., a promoter sequence from an Erk gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from an Erk gene or from another gene, a 3'UTR, e.g., a 3'UTR from an Erk gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of Erk protein is increased by increasing the level of expression of an endogenous Erk gene, e.g., by increasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene is increased by: altering the regulatory sequence of the endogenous Erk gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the Erk gene to be transcribed more efficiently.

Another aspect of the invention features a method of screening for agents which increase or decrease fibrosis and/or angiogenesis to thereby treat disorders associated with increased or decreased fibrosis, e.g., the disorders mentioned above. The method includes: providing a cell, tissue, or subject, e.g., an experimental animal, e.g., an animal model for a fibrosis related disorder; contacting the cell, tissue or subject with a test agent; and determining whether the test agent inhibits a component of the VEGF signaling pathway.

In preferred embodiments, the screening can include screening for: an agent that inhibits VEGF activity; an agent that inhibits VEGFR signaling, e.g., an agent that inhibits the interaction between VEGF and a VEGFR; an agent that inhibits PI3 kinase activity; an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase; an agent that inhibits AKT activity; and/or an agent that inhibits ERK activity.

In some embodiments, the method can include one or more of the following steps:

applying VEGF to cells in culture, e.g., BREC or BREP; applying a candidate drug or a combinatorial library of drugs; assaying for levels of CTGF. CTGF levels can be assayed various methods commonly practiced in the art. In one embodiment, CTGF levels are assayed by Northern analysis for CTGF mRNA expression. In another embodiment CTGF levels are assayed by detect CTGF protein, e.g., with an antibody, e.g., using an ELISA assay or a Western blot assay. In another embodiment, CTGF transcription is monitored by assaying for a reporter protein, e.g., lacZ, chloramphenicol acetyltransferase (CAT), green fluorescent protein or variants thereof, and other fluorescent proteins and variants thereof, where the gene encoding the reporter protein is fused to the CTGF promoter and the ensemble is transfected into the cells. The methods can further include administering an agent identified by the screening methods described herein to an animal, e.g., an animal model for a fibrotic disorder.

Detailed Description

The inventors have discovered that VEGF can modulate the activity and/or expression of CTGF in a time- and concentration-dependent manner in cells and/or tissues with VEGF receptors, e.g., in endothelial cells, e.g., microvascular endothelial cells such as human retinal endothelial cells or bovine retinal endothelial cells (BREC), and in contractile cells, e.g., in capillary pericytes, e.g., in human or bovine retinal pericytes (BRPC). VEGF-induced modulation of CTGF can occur via the PI3 kinase pathway, e.g., via the KDR receptor-PI3 kinase-Erk pathway (e.g., in BREC), or the Flt1-PI3 kinase-Akt pathway (e.g., in BRPC). Modulation of CTGF via the VEGF pathway can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis-related disorders described herein.

VEGF receptor (VEGFR), e.g., Flt1 (VEGFR1), KDR/Flk1 (VEGFR2), Flt4 (VEGFR3), NP1, tie, or tie-2, can mediate increases in CTGF mRNA expression. The ability of Flt1 to induce increases in CTGF mRNA levels is demonstrated in the pericytes that have predominantly Flt1 receptors. In addition, placenta growth factor (PIGF), a Flt1 receptor-specific ligand, was able to induce CTGF mRNA levels in BRPC but not in BREC, indicating that VEGF can induce CTGF mRNA by activating through Flt1 in pericytes, e.g., BRPC. The KDR/Flk1 receptors in the endothelial cells can also induce CTGF gene expression since KDR/Flk1 receptors are the predominant VEGF receptors in endothelial cells.

The VEGF dose-response curves for CTGF in both BRPC and BREC are similar and

suggest that VEGF binds to high affinity receptors, consistent with the known Kd values of Flt1 and KDR/Flk1 at 10-100 pM. While not wanting to be bound by theory, VEGF-induced CTGF mRNA is most likely due to an induction of transcription rather than altering the half-life of CTGF mRNA since the addition of VEGF failed to change the degradation rates of CTGF mRNA. The time course of the action of VEGF on CTGF (which required 6-9 h) suggests this is potentially a chronic action of VEGF. In addition, the time needed to achieve maximum effect is also consistent with the calculated mRNA half-life of CTGF mRNA of 2-4 h.

From a biological perspective, the effects of VEGF on CTGF mRNA could potentially have important physiological impact for several reasons. First, the increase in CTGF mRNA results in increased protein levels. Second, the VEGF concentration that was minimally active (0.25 ng/ml) can easily bind and activate a significant percentage of the VEGFR-1, -2 receptors. Third, this low level of VEGF may exist even in non-pathological states, suggesting that low levels of VEGF may have physiological actions on maintaining extracellular matrix production via the induction of CTGF. At 2.5-25 ng/ml VEGF which are encountered in hypoxic and angiogenic states (Aiello et al. (1994) N. Engl. J. Med. 331, 1480-1487), the induction of CTGF expression by VEGF could potentially induce the fibrosis that frequently accompanies neovascularization. This possibility is supported further by the demonstration that the protein levels of CTGF expression were increased 10 h after the addition of VEGF that was consistent with the maximum increase in the mRNA levels at 6-9 h. In addition, the potency of VEGF on CTGF expression appeared to be similar to TGF-beta1, suggesting that both of them could induce fibrosis associated with neovascularization.

The activation of the endogenous tyrosine kinases of KDR/Flk1s can stimulate multiple signaling pathways, including Ras-Erk, PI3-kinase-Akt, and phospholipase CK-PKC cascades. The results in BREC described herein indicate that VEGF can increase the tyrosine phosphorylation of KDR/Flk1 and its interaction with p85 subunit of PI3-kinase. In addition, VEGF also activates the Erk1/2 pathway in BREC. In contrast, VEGF was unable to activate Erk1/2 but stimulated the activation of PI3-kinase and phosphorylation of Akt in BRPC. These results indicate that the signaling pathways for Flt1 in vascular cells are different from those for KDR/Flk1. The lack of effect on Erk1/2 activation also supports the hypothesis that Flt1, unlike KDR/Flk1, is not involved in mitogenic actions.

The results described herein provide strong evidence that VEGF is inducing CTGF gene

expression in both endothelial cells and pericytes via VEGFR1 or -R2 by the activation of PI3-kinase and Akt. This evidence includes the ability of wortmannin, a PI3-kinase inhibitor, to inhibit the effects of VEGFs in both cell types. Adenovirus containing dominant negative mutants of p85 subunit of PI3-kinase or Akt inhibited the action of VEGFs, whereas overexpression of dominant negative mutants of Ras and Erk1 by adenovirus vectors did not inhibit CTGF mRNA expression. Conversely, the overexpression of constitutive active Akt increased CTGF mRNA expression by 2.5-fold. The overexpression of either the wild type or dominant negative of PKC isoform did not alter the effects of VEGF on CTGF mRNA levels.

In summary, the results described herein show that VEGF can induce the expression of CTGF via VEGFR, e.g., Flt1, KDR/Flik1, Flt4, NP-1, tie, or tie-2, by the selectively activated PI3-kinase-Akt pathway but mostly independent of the Ras-Erk pathway. In addition, the spectrum of signaling pathways can be different among different VEGFRs, possibly reflecting their physiological roles. These results support the conclusion that VEGF, through its effects on CTGF expression, has physiological roles such as the maintenance of capillary strength and wound healing via the extracellular matrix production. In disease states, VEGF-induced CTGF may cause the proliferation of fibrocellular components in retinal neovascular diseases such as proliferative diabetic retinopathy and age-related macular degeneration.

Modulation of CTGF through the VEGF pathway, e.g., modulation of components of the VEGF pathway, e.g., Flt1, KDR, Flt4, neuropilin-1, PI3 kinase, Akt, or Erk, can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis related disorders. CTGF has been associated with a number of fibrosis-related disorders, e.g., scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; renal disease; atherosclerotic plaques; inflammatory bowel disease; Crohn's disease; arthritic joints; cancer, e.g., invasive breast carcinoma, dermatofibromas, angiolioma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture (J. Invest. Dermatol. 1996 106:729-733; J Biol Chem. 2001 276:10594-601; Int J Biochem Cell Biol. 1998 30:909-22; J Eur Acad Dermatol Venereol. 1998 11:1-8; Int J Biochem Cell Biol. 1998 Aug;30(8):909-22;

Ann Surg. 1999 Jul;230(1):63-71; J Cell Physiol. 1999 Oct;181(1):153-9; Curr Opin Nephrol Hypertens. 1999 Sep;8(5):543-8; J Am Soc Nephrol. 2001 Mar;12(3):472-84; J Rheumatol. 2000 Jan;27(1):149-54; J Mol Cell Cardiol. 2000 Oct;32(10):1805-19). Other fibrosis related diseases in which CTGF may be involved include macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments.

Generation of Fragments

Fragments of components of the VEGF signaling pathway, e.g., VEGF, VEGFRs, PI3 kinase, AKT, can be used to increase VEGF signaling, thereby increasing CTGF activity, thereby increasing fibrosis or angiogenesis. For example, various fragments of VEGF are known and described, for example, in U.S. Patent No.: 5,935,820.

Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.

Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Random Methods

Amino acid sequence variants of a protein, e.g., a VEGF signaling pathway component described herein, can be prepared by random mutagenesis of DNA which encodes a protein or a

particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants, e.g., screening for CTGF modulating activity or VEGF signaling agonist or antagonist activity, are elsewhere herein.)

PCR Mutagenesis

In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, *Technique* 1:11-15). This is a very powerful and relatively rapid method of introducing random mutations. The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn²⁺ to the PCR reaction. The pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.

Saturation Mutagenesis

Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, *Science* 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA *in vitro*, and synthesis of a complimentary DNA strand. The mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.

Degenerate Oligonucleotides

A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos.*

Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Directed Mutagenesis

Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

Alanine Scanning Mutagenesis

Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (*Science* 244:1081-1085, 1989). In alanine scanning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine). Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.

Oligonucleotide-Mediated Mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (*DNA* 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (*Proc. Natl. Acad. Sci. (1978) USA*, 75: 5765).

Cassette Mutagenesis

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (*Gene*, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are comparable with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated desired protein subunit DNA sequence.

Combinatorial Mutagenesis

Combinatorial mutagenesis can also be used to generate mutants. For example, the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.

Primary High-Through-Put Methods for Screening Libraries of Peptide Fragments or Homologs

Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, assembly into a trimeric molecules, binding to natural ligands, e.g., a receptor or substrates, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two Hybrid Systems

Two hybrid (interaction trap) assays can be used to identify a protein that interacts with a component of the VEGF signaling pathway, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 kinase (e.g., p85), AKT, ERK. These may include agonists, superagonists, and antagonists of the components. (The subject protein and a protein it interacts with are used as the bait protein and fish proteins.). These assays rely on detecting the reconstitution of a functional transcriptional activator mediated by protein-protein interactions with a bait protein. In particular, these assays make use of chimeric genes which express hybrid proteins. The first hybrid comprises a DNA-binding domain fused to the bait protein. e.g., a VEGF or VEGFR

molecule or a fragment thereof. The second hybrid protein contains a transcriptional activation domain fused to a "fish" protein, e.g. an expression library. If the fish and bait proteins are able to interact, they bring into close proximity the DNA-binding and transcriptional activator domains. This proximity is sufficient to cause transcription of a reporter gene which is operably linked to a transcriptional regulatory site which is recognized by the DNA binding domain, and expression of the marker gene can be detected and used to score for the interaction of the bait protein with another protein.

Display Libraries

In one approach to screening assays, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands, e.g., receptors, can be used to detect homolog which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.

A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10^{13} phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E. coli* filamentous phages M13, fd., and f1 are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH₂-terminal end of pIII and phage bearing such epitopes recovered from a large excess of phage

lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J.* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

A common approach uses the maltose receptor of *E. coli* (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) *EMBO* 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) *Vaccines* 9, pp. 387-392), PhoE (Agterberg, et al. (1990) *Gene* 88, 37-45), and PAL (Fuchs et al. (1991) *Bio/Tech* 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. (1989) *Appl. Environ. Microbiol.* 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptides copies on the host cells (Kuwajima et al. (1988) *Bio/Tech.* 6, 1080-1083). Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the *Staphylococcus* protein A and the outer membrane protease IgA of *Neisseria* (Hansson et al. (1992) *J. Bacteriol.* 174, 4239-4245 and Klauser et al. (1990) *EMBO J.* 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull et al. (1992) *PNAS USA* 89:1865-1869). This system uses a plasmid containing the LacI gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the LacI-peptide fusion binds tightly to

the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251). These particular biases are not a factor in the LacI display system.

The number of small peptides available in recombinant random libraries is enormous. Libraries of 10^7 - 10^9 independent clones are routinely prepared. Libraries as large as 10^{11} recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, an *in vitro* system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.

In one application of this method (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251), a molecular DNA library encoding 10^{12} decapeptides was constructed and the library expressed in an *E. coli* S30 *in vitro* coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) *Anal. Biochem.* 204:357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

Secondary Screens

The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the

desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest (e.g., VEGF or PI3 kinase) and a ligand (e.g., VEGFR and AKT, respectively) can be used to identify antagonists from a group of peptide fragments isolated through one of the primary screens described above.

Therefore, methods for generating fragments and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine to perform for one skilled in the art to obtain analogs and fragments.

Peptide Mimetics

The invention also provides for reduction of the protein binding domains of the subject polypeptides, e.g., VEGF or VEGFR, to generate mimetics, e.g. peptide or non-peptide agents. See, for example, "Peptide inhibitors of human papillomavirus protein binding to retinoblastoma gene protein" European patent applications EP 0 412 762 and EP 0 031 080.

Non-hydrolyzable peptide analogs of critical residues can be generated using benzodiazepine (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans 1*:1231), and β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71).

Fusion Proteins

Polypeptides for modulating the level of a component of the VEGF signaling pathway can be fused to another protein or portion thereof. For example, a VEGF protein or antagonist or fragment thereof, can be operably linked to another polypeptide moiety to enhance solubility. Examples of a protein which can be fused with a protein or portions thereof include a plasma protein or fragment thereof, which can improve the circulating half life. For example, the fusion

protein can be a VEGF fragment-immunoglobulin (Ig) fusion protein in which the VEGF sequence is fused to a sequence derived from the immunoglobulin superfamily. Several soluble fusion protein constructs have been disclosed wherein the extracellular domain of a cell surface glycoprotein is fused with the constant F(c) region of an immunoglobulin. For example, Capon et al. (1989) *Nature* 337(9):525-531, provide guidance on generating a longer lasting CD4 analog by fusing CD4 to an immunoglobulin (IgG1). *See also*, Capon et al., U.S. Patent Numbers: 5,116,964 and 5,428,130 (CD4-IgG fusion constructs); Linsley et al., U.S. Patent Number 5,434,131 (CTLA4-IgG1 and B7-IgG1 fusion constructs); Linsley et al. (1991) *J. Exp. Med.* 174:561-569 (CTLA4-IgG1 fusion constructs); and Linsley et al. (1991) *J. Exp. Med.* 173:721-730 (CD28-IgG1 and B7-IgG1 fusion constructs). Such fusion proteins have proven useful for modulating receptor-ligand interactions and reducing inflammation *in vivo*. For example, fusion proteins in which an extracellular domain of cell surface tumor necrosis factor receptor (TNFR) proteins has been fused to an immunoglobulin constant (Fc) region have been used *in vivo*. *See, for example*, Moreland et al. (1997) *N. Engl. J. Med.* 337(3):141-147; and, van der Poll et al. (1997) *Blood* 89(10):3727-3734).

Antibodies

The invention also includes antibodies specifically reactive with a component of the VEGF signaling pathway described herein. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made as described herein by using standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)).

A component of the VEGF signaling pathway described herein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind the component using standard techniques for polyclonal and monoclonal antibody preparation. The full-length component protein can be used or, alternatively, antigenic peptide fragments of the component can be used as immunogens.

Typically, a peptide is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, a recombinant VEGF peptide, or a chemically synthesized VEGF peptide or antagonist. *See, e.g.*, U.S. Patent No. 5,460,959; and co-pending U.S. applications USSN 08/334,797; USSN 08/231,439; USSN 08/334,455; and USSN 08/928,881

which are hereby expressly incorporated by reference in their entirety. The nucleotide and amino acid sequences of components of the VEGF signaling pathway described herein are known. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic VEGF preparation induces a polyclonal anti-VEGF antibody response.

Antibodies to a component of the VEGF signaling pathway, or fragments thereof, can be used to inhibit the levels of such a component, thereby decreasing CTGF activity. Examples of antibody fragments include F(v), Fab, Fab' and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope. A monoclonal antibody composition thus typically displays a single binding affinity for a particular protein with which it immunoreacts.

Additionally, antibodies produced by genetic engineering methods, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, can be used. Such chimeric and humanized monoclonal antibodies can be produced by genetic engineering using standard DNA techniques known in the art, for example using methods described in Robinson et al.

International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al., *Science* 240:1041-1043, 1988; Liu et al., *PNAS* 84:3439-3443, 1987; Liu et al., *J. Immunol.* 139:3521-3526, 1987; Sun et al. *PNAS* 84:214-218, 1987; Nishimura et al., *Canc. Res.* 47:999-1005, 1987; Wood et al., *Nature* 314:446-449, 1985; and Shaw et al., *J. Natl. Cancer Inst.* 80:1553-1559, 1988); Morrison, S. L., *Science* 229:1202-1207, 1985; Oi et al., *BioTechniques* 4:214, 1986; Winter U.S. Patent 5,225,539; Jones et al., *Nature* 321:552-525, 1986; Verhoeven et al., *Science* 239:1534, 1988; and Beidler et al., *J. Immunol.* 141:4053-4060, 1988.

In addition, a human monoclonal antibody directed against a component of the VEGF signaling pathway described herein can be made using standard techniques. For example, human monoclonal antibodies can be generated in transgenic mice or in immune deficient mice

engrafted with antibody-producing human cells. Methods of generating such mice are described, for example, in Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication WO 92/03917; Kay et al. PCT publication WO 93/12227; Kay et al. PCT publication 94/25585; Rajewsky et al. PCT publication WO 94/04667; Dittulio et al. PCT publication WO 95/17085; Lonberg, N. et al. (1994) *Nature* 368:856-859; Green, L.L. et al. (1994) *Nature Genet.* 7:13-21; Morrison, S.L. et al. (1994) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. (1993) *Year Immunol.* 7:33-40; Choi et al. (1993) *Nature Genet.* 4:117-123; Tuailon et al. (1993) *PNAS* 90:3720-3724; Bruggeman et al. (1991) *Eur J Immunol.* 21:1323-1326; Duchosal et al. PCT publication WO 93/05796; U.S. Patent Number 5,411,749; McCune et al. (1988) *Science* 241:1632-1639; Kamel-Reid et al. (1988) *Science* 242:1706; Spanopoulou (1994) *Genes & Development* 8:1030-1042; Shinkai et al. (1992) *Cell* 68:855-868). A human antibody-transgenic mouse or an immune deficient mouse engrafted with human antibody-producing cells or tissue can be immunized with a component of the VEGF signaling pathway described herein or an antigenic peptide thereof and splenocytes from these immunized mice can then be used to create hybridomas. Methods of hybridoma production are well known.

Human monoclonal antibodies against components of the VEGF signaling pathway described herein can also be prepared by constructing a combinatorial immunoglobulin library, such as a Fab phage display library or a scFv phage display library, using immunoglobulin light chain and heavy chain cDNAs prepared from mRNA derived from lymphocytes of a subject. See, e.g., McCafferty et al. PCT publication WO 92/01047; Marks et al. (1991) *J. Mol. Biol.* 222:581-597; and Griffiths et al. (1993) *EMBO J.* 12:725-734. In addition, a combinatorial library of antibody variable regions can be generated by mutating a known human antibody. For example, a variable region of a human antibody known to bind VEGF, can be mutated, by for example using randomly altered mutagenized oligonucleotides, to generate a library of mutated variable regions which can then be screened to bind to VEGF. Methods of inducing random mutagenesis within the CDR regions of immunoglobulin heavy and/or light chains, methods of crossing randomized heavy and light chains to form pairings and screening methods can be found in, for example, Barbas et al. PCT publication WO 96/07754; Barbas et al. (1992) *Proc. Nat'l Acad. Sci. USA* 89:4457-4461.

The immunoglobulin library can be expressed by a population of display packages, preferably derived from filamentous phage, to form an antibody display library. Examples of methods and reagents particularly amenable for use in generating antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT publication WO 92/18619; Dower et al. PCT publication WO 91/17271; Winter et al. PCT publication WO 92/20791; Markland et al. PCT publication WO 92/15679; Breitling et al. PCT publication WO 93/01288; McCafferty et al. PCT publication WO 92/01047; Garrard et al. PCT publication WO 92/09690; Ladner et al. PCT publication WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum Antibod Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *supra*; Hawkins et al. (1992) *J Mol Biol* 226:889-896; Clackson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc Acid Res* 19:4133-4137; and Barbas et al. (1991) *PNAS* 88:7978-7982. Once displayed on the surface of a display package (e.g., filamentous phage), the antibody library is screened to identify and isolate packages that express an antibody that binds a component of the VEGF signaling pathway described herein. In a preferred embodiment, the primary screening of the library involves panning with an immobilized component of the VEGF signaling pathway described herein and display packages expressing antibodies that bind immobilized a component of the VEGF signaling pathway described herein are selected.

Antisense Nucleic Acid Sequences

Nucleic acid molecules which are antisense to a nucleotide encoding a component of the VEGF signaling pathway described herein, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 Kinase, AKT, can be used as an agent which inhibits expression of the component. An "antisense" nucleic acid includes a nucleotide sequence which is complementary to a "sense" nucleic acid encoding the component, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof. For example, an antisense nucleic acid molecule which antisense to the "coding region" of the coding strand of a nucleotide sequence encoding the component can be used.

The coding strand sequences encoding components of the VEGF signaling pathway described herein are known. Given the coding strand sequences encoding these components, antisense nucleic acids can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiacytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).

Administration

An agent which modulates the level of expression of a component of the VEGF signaling pathway described herein can be administered to a subject by standard methods. For example, the agent can be administered by any of a number of different routes including intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal. In one embodiment, the VEGF signaling pathway modulating agent can be administered topically.

The agent which modulates protein levels, e.g., nucleic acid molecules, polypeptides, fragments or analogs, modulators, and antibodies (also referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically include the nucleic acid molecule, polypeptide, modulator, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances are known. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition can be formulated to be compatible with its intended route of administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be

fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a VEGF polypeptide or anti-VEGF antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a

disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

The nucleic acid molecules described herein can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al., *PNAS* 91:3054-3057, 1994). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

The agent which modulates the activity of a component of the VEGF signaling pathway described herein can be administered by locally administration, e.g., topical administration. The agent can be applied once or it can be administered continuously, e.g., the agent is administered with sufficient frequency such that the affect on the VEGF protein level is maintained for a selected period, e.g., 5, 10, 20, 30, 50, 90, 180, 365 days or more. The administration of an agent which modulates, e.g., increases or inhibits, the level of a component of the VEGF signaling pathway described herein, e.g., a VEGF polypeptide or an anti-VEGF antibody, can also be repeated.

Transition Metals

Transition metal ions have been shown to enhance expression of the VEGF gene thereby increasing VEGF protein levels. *See* U.S. Patent No.: 5,480,975. Thus, in one aspect, a transition metal ion can be used to increase CTGF, thereby increasing fibrosis or angiogenesis, by increasing expression of VEGF.

The transition metals are the group consisting of the fourth, fifth and sixth levels of the periodic table and which fill the d orbital. They include such elements as Ni, Co, Mn, Zn, V, Cr, Fe, Cu, Mo, etc. The preferred candidate metal ions for use are manganese, cobalt and nickel.

Selection of other appropriate metal ions involves determining whether, and at what level, the ion will induce VEGF expression. Particularly for systemic applications, selection also involves a review of toxicity. Suitable techniques for those determinations are provided below in U.S. Patent No.: 5,480,795. Preferred ions are those with a substantial range between VEGF induction and toxicity.

The transition metal can be administered internally (systemic or local administration) in the form of a salt or free ion in a biologically compatible tablet or capsule, gel, or liquid, or it can be administered externally in the form of a biologically compatible powder, salve, liquid, or transdermal patch. Any physiologically acceptable anion such as chloride, sulfate, etc., can be included in the composition.

Appropriate release rates and dosages can be determined in order to affect the targeted tissue without substantial systemic effect. For example, these parameters can be determined as described in U.S. Patent No.: 5,480,795.

Gene Therapy

The gene constructs of the invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a component of the VEGF signaling pathway described herein. The invention features expression vectors for in vivo transfection and expression of a component of the VEGF signaling pathway described herein in particular cell types so as to reconstitute the function of, or alternatively, antagonize the function of the component in a cell in which that polypeptide is misexpressed. Expression constructs of such components may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO4 precipitation carried out in vivo.

A preferred approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding a component of the VEGF signaling pathway described herein. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes in vivo, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased

the utility of retroviruses for gene therapy, and defective retroviruses are characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). A replication defective retrovirus can be packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in *Current Protocols in Molecular Biology*, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include *Crip, *Cre, *2 and *Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See, for example, Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including epithelial cells (Rosenfeld et al. (1992) cited *supra*). Furthermore, the virus particle is relatively

stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis *in situ* where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267).

Yet another viral vector system useful for delivery of the subject gene is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzychka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski et al. (1989) *J. Virol.* 63:3822-3828; and McLaughlin et al. (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985) *Mol. Cell. Biol.* 4:2072-2081; Wondisford et al. (1988) *Mol. Endocrinol.* 2:32-39; Tratschin et al. (1984) *J. Virol.* 51:611-619; and Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790).

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a component of the VEGF signaling pathway described herein in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the subject gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes. Other embodiments include plasmid injection systems

such as are described in Meuli et al. (2001) J Invest Dermatol. 116(1):131-135; Cohen et al. (2000) Gene Ther 7(22):1896-905; or Tam et al. (2000) Gene Ther 7(21):1867-74.

In a representative embodiment, a gene encoding a component of the VEGF signaling pathway described herein can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al. (1992) No Shinkei Geka 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).

In clinical settings, the gene delivery systems for the therapeutic gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) PNAS 91: 3054-3057).

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced in tact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

Cell Therapy

A component of the VEGF signaling pathway described herein can also be increased in a subject by introducing into a cell, e.g., an endothelial cell, fibroblast or a keratinocyte, a nucleotide sequence that modulates the production of the component, e.g., a nucleotide sequence encoding a component polypeptide or functional fragment or analog thereof, a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an

enhancer sequence, e.g., 5' untranslated region (UTR), e.g., a 5' UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3' UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence; or another sequence that modulates the expression of VEGF. The cell can then be introduced into the subject.

Primary and secondary cells to be genetically engineered can be obtained from a variety of tissues and include cell types which can be maintained propagated in culture. For example, primary and secondary cells include fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells), endothelial cells, glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells (myoblasts) and precursors of these somatic cell types. Primary cells are preferably obtained from the individual to whom the genetically engineered primary or secondary cells are administered. However, primary cells may be obtained for a donor (other than the recipient).

The term "primary cell" includes cells present in a suspension of cells isolated from a vertebrate tissue source (prior to their being plated i.e., attached to a tissue culture substrate such as a dish or flask), cells present in an explant derived from tissue, both of the previous types of cells plated for the first time, and cell suspensions derived from these plated cells. The term "secondary cell" or "cell strain" refers to cells at all subsequent steps in culturing. Secondary cells are cell strains which consist of secondary cells which have been passaged one or more times.

Primary or secondary cells of vertebrate, particularly mammalian, origin can be transfected with an exogenous nucleic acid sequence which includes a nucleic acid sequence encoding a signal peptide, and/or a heterologous nucleic acid sequence, e.g., encoding a component of the VEGF signaling pathway described herein or an agonist or antagonist thereof, and produce the encoded product stably and reproducibly in vitro and in vivo, over extended periods of time. A heterologous amino acid can also be a regulatory sequence, e.g., a promoter, which causes expression, e.g., inducible expression or upregulation, of an endogenous sequence. An exogenous nucleic acid sequence can be introduced into a primary or secondary cell by homologous recombination as described, for example, in U.S. Patent No.: 5,641,670, the contents of which are incorporated herein by reference. The transfected primary or secondary cells may also include DNA encoding a selectable marker which confers a selectable phenotype upon them, facilitating their identification and isolation.

Vertebrate tissue can be obtained by standard methods such a punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest. For example, punch biopsy is used to obtain skin as a source of fibroblasts or keratinocytes. A mixture of primary cells is obtained from the tissue, using known methods, such as enzymatic digestion or explanting. If enzymatic digestion is used, enzymes such as collagenase, hyaluronidase, dispase, pronase, trypsin, elastase and chymotrypsin can be used.

The resulting primary cell mixture can be transfected directly or it can be cultured first, removed from the culture plate and resuspended before transfection is carried out. Primary cells or secondary cells are combined with exogenous nucleic acid sequence to, e.g., stably integrate into their genomes, and treated in order to accomplish transfection. As used herein, the term "transfection" includes a variety of techniques for introducing an exogenous nucleic acid into a cell including calcium phosphate or calcium chloride precipitation, microinjection, DEAE-dextrin-mediated transfection, lipofection or electrophoration, all of which are routine in the art.

Transfected primary or secondary cells undergo sufficient number doubling to produce either a clonal cell strain or a heterogeneous cell strain of sufficient size to provide the therapeutic protein to an individual in effective amounts. The number of required cells in a transfected clonal heterogeneous cell strain is variable and depends on a variety of factors, including but not limited to, the use of the transfected cells, the functional level of the exogenous DNA in the transfected cells, the site of implantation of the transfected cells (for example, the number of cells that can be used is limited by the anatomical site of implantation), and the age, surface area, and clinical condition of the patient.

The transfected cells, e.g., cells produced as described herein, can be introduced into an individual to whom the product is to be delivered. Various routes of administration and various sites (e.g., renal sub capsular, subcutaneous, central nervous system (including intrathecal), intravascular, intrahepatic, intrasplanchinc, intraperitoneal (including intraomental), intramuscularly implantation) can be used. One implanted in individual, the transfected cells produce the product encoded by the heterologous DNA or are affected by the heterologous DNA itself. For example, an individual who suffers from fibrosis is a candidate for implantation of cells producing an antagonist of a component of the VEGF signaling pathway described herein.

An immunosuppressive agent e.g., drug, or antibody, can be administered to a subject at a dosage sufficient to achieve the desired therapeutic effect (e.g., inhibition of rejection of the

cells). Dosage ranges for immunosuppressive drugs are known in the art. See, e.g., Freed et al. (1992) N. Engl. J. Med. 327:1549; Spencer et al. (1992) N. Engl. J. Med. 327:1541' Widner et al. (1992) n. Engl. J. Med. 327:1556). Dosage values may vary according to factors such as the disease state, age, sex, and weight of the individual.

Examples

Example 1: VEGF modulates CTGF mRNA Expression

The effects of VEGF on the expression of CTGF mRNA were studied by Northern blot analysis in BREC and BRPC. 25 ng/ml VEGF increased CTGF mRNA (~2.4 kb) levels in a time-dependent manner, reaching a maximum after 6 h in BREC (3.1 ± 0.70 -fold, $p < 0.001$) and after 9 h in BRPC (2.0 ± 0.22 -fold, $p < 0.01$).

The dose response to VEGF-induced CTGF mRNA expression was studied after 6 h of VEGF stimulation. The expression of CTGF mRNA was up-regulated in a dose-dependent manner, with significant increases observed at concentrations as low as 0.25 ng/ml in both BREC and BRPC. Maximal increases were observed at VEGF concentrations of 25 ng/ml in both BREC and BRPC.

Since BREC and BRPC may express both KDR and Flt1, we examined the effects of PIGF, a Flt1-specific ligand, on the induction of CTGF gene expression in vascular cells. CTGF mRNA levels were not affected after stimulation of 25 ng/ml of PIGF in BREC. In contrast, PIGF increased CTGF mRNA after 3 h of stimulation, which peaked after 9 h in BRPC (1.9 ± 0.30 -fold, $p < 0.01$), suggesting that VEGF-induced CTGF gene expression was mediated primarily by KDR in BREC and Flt1 in BRPC.

Example 2: VEGF Induction of CTGF Protein Production

To determine if the effects of VEGF on CTGF mRNA were correlated with its protein level, CTGF protein expression was assessed by Western blot analysis using anti-human CTGF antibody. The detected size of CTGF protein was ~38 kDa in both BREC and BRPC. VEGF (25 ng/ml) increased the level of CTGF protein after 10 h in both BREC and BRPC. Comparative studies were performed on the effects of VEGF (25 ng/ml) and TGF- β 1 (10 ng/ml) on the expression of CTGF mRNA and protein. VEGF and TGF- β 1 increased CTGF protein expression by a similar amount (2.5 ± 0.4 - and 2.8 ± 0.8 -fold, respectively, in BREC). CTGF

mRNA levels were also increased a similar extent (3.0 ± 0.3 - and 3.3 ± 0.5 -fold, respectively).

Example 3: Effects of VEGF on the Half-life of CTGF mRNA

The effects of VEGF on the stability of CTGF mRNA were examined. Northern blot analyses were performed with addition of actinomycin D (5 μ g/ml) after 6 h of VEGF (25 ng/ml) stimulation. In BREC and BRPC3, the half-life of CTGF mRNA was 1.7 and 3.6 h, respectively. There was no significant difference between VEGF-treated and -untreated cells.

Example 4: Effects of Cycloheximide on CTGF mRNA Regulation

In order to examine the possibility that VEGF regulates CTGF mRNA expression through new protein synthesis of cytokines or transcription factors, cells were treated for 6 h with VEGF (25 ng/ml) and a protein synthesis inhibitor, cycloheximide (10 μ g/ml). Cycloheximide did not prevent the increase of CTGF mRNA. Addition of both VEGF and cycloheximide increased CTGF mRNA 2.4 ± 0.41 -fold in BREC and 2.5 ± 0.40 -fold in BRPC after 6 h as compared with cycloheximide alone ($p < 0.01$). These data suggest that the stimulation of CTGF mRNA expression by VEGF was not induced by increased synthesis of a regulatory protein.

Example 5: Involvement of Erk and PI3-Kinase-Akt in VEGF Signaling

Since Erk and PI3-kinase-Akt pathways have been reported to play central roles in VEGF signaling and biological actions, it was investigated whether or not VEGF can activate Erk and PI3-kinase-Akt pathways equally in BREC and BRPC. Immunoblot analysis of immunoprecipitates of KDR from BREC stimulated with VEGF or PIGF using an antibody to phosphotyrosine and PI3-kinase p85 subunit demonstrated that VEGF, but not PI GF, promoted the tyrosine phosphorylation of KDR and interactions of KDR and p85 subunit of PI3-kinase. In contrast, Immunoblot analysis of immunoprecipitates of Flt1 from BRPC stimulated with VEGF or PI GF demonstrated that both VEGF and PI GF increased the tyrosine phosphorylation of Flt1 and interactions of Flt1 and p85 subunit of PI3-kinase. These data suggest that VEGF can activate the receptor tyrosine phosphorylation and interaction with PI3-kinase p85 subunit in both KDR and Flt1.

To investigate the activation of Akt and Erk, we next performed immunoblot analysis with anti-phosphorylated Akt or anti-phosphorylated Erk antibodies using total cell lysates from BREC or BRPC stimulated with VEGF. VEGF induced phosphorylation of both Akt and Erk in BREC by 3.1- and 5.8-fold, but only induced phosphorylation of Akt in BRPC by 2.6-fold. No effect on Erk phosphorylation was observed in BRPC. These data suggest that VEGF activated both Erk and PI3-kinase-Akt pathways in BREC, but stimulated only PI3-kinase-Akt pathway in BRPC.

Since the activation of PI3-kinase by VEGF has not been reported in BRPC, we studied the effects of VEGF on PI3-kinase activity in BRPC. The addition of VEGF (25 ng/ml) increased PI3-kinase activity in a time-dependent manner by 2.1 ± 0.27 -fold ($p < 0.01$) after 5 min and by 1.6 ± 0.17 -fold ($p < 0.05$) after 10 min in BRPC.

Example 6: Effects of PKC, Erk, and PI3-Kinase Inhibition on VEGF-induced CTGF Expression

To investigate the signaling pathways involved in VEGF-induced CTGF expression, the effects of inhibition of PKC, Erk, and PI3-kinase were determined. Cells were treated with 25 ng/ml VEGF for 6 h after pretreatment with the kinase inhibitor GF 109203X, a classical and novel PKC-specific inhibitor (1 μ M); PD98059, a MAPK/Erk kinase inhibitor (20 μ M); or wortmannin, a PI3-kinase inhibitor (100 nM). Neither GF 109203X nor PD98059 had significant effects on VEGF-induced CTGF mRNA expression, but wortmannin inhibited the effects of VEGF by $88 \pm 6.5\%$ ($p < 0.01$) in BREC and $78 \pm 22\%$ ($p < 0.01$) in BRPC. To confirm further the involvement of PI3-kinase in VEGF-induced CTGF expression, recombinant adenoviruses were used encoding dominant negative K-ras (DNRas), dominant negative extracellular signal-regulated kinase (DNERk), or $\Delta p85$ of PI3-kinase. BREC were transfected with each adenoviral vector, followed by stimulation with 25 ng/ml VEGF for 6 h. Neither DNRas nor DNERk had significant effects on VEGF-induced increase in CTGF mRNA, but $\Delta p85$ of PI3-kinase completely inhibited VEGF-induced CTGF expression ($p < 0.001$).

Example 7: Role of PKC ζ and Akt/PKB in VEGF-induced CTGF Expression

Since it has been reported that atypical PKC and Akt/PKB have significant roles as signaling molecules downstream of PI3-kinase, the involvement of PKC ζ and Akt in this process were examined. BREC were infected with each adenoviral vector, followed by

stimulation with 25 ng/ml VEGF for 6 h. Neither wild type PKC ζ nor dominant negative PKC ζ (DNPKC ζ) had significant effects on VEGF-induced increase in CTGF mRNA. In contrast, infection with constitutive active Akt (CAAkt) increased CTGF mRNA expression 2.1 ± 0.21 -fold ($p < 0.01$) without VEGF and 2.5 ± 0.40 -fold with VEGF. Overexpression with adenoviral vector containing dominant negative Akt (DNAkt) inhibited VEGF-induced CTGF expression by $85 \pm 13\%$ ($p < 0.01$).

Example 8: Methods

A) Materials-- Endothelial cell basal medium was purchased from Clonetics (San Diego, CA). Endothelial cell growth factor was purchased from Roche Molecular Biochemicals. Dulbecco's modified Eagle's medium and fetal bovine serum were obtained from Life Technologies, Inc. VEGF, placenta growth factor (PIGF), TGF β 1, and anti-CTGF antibody were ordered from R & D Systems (Minneapolis, MN). Anti-KDR (Flk1) and anti-Flt1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A-Sepharose was purchased from Amersham Pharmacia Biotech. Anti-phospho-Erk, anti-Erk, anti-phospho-Akt, and anti-Akt were purchased from New England Biolabs (Beverly, MA). Anti-p85 and anti-phosphotyrosine were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Phosphatidylinositol (PI) was purchased from Avanti (Alabaster, AL), and PD98059, wortmannin, and GF 109203X were obtained from Calbiochem. All other materials were ordered from Fisher and Sigma.

B) Cell Culture-- Primary cultures of bovine retinal endothelial cells (BREC) and pericytes (BRPC) were isolated by homogenization and a series of filtration steps as described previously. BREC were subsequently cultured with endothelial cell basal medium supplemented with 10% plasma-derived horse serum, 50 mg/liter heparin, and 50 μ g/ml endothelial cell growth factor. BRPC were cultured in Dulbecco's modified Eagle's medium with 5.5 mM glucose and 20% fetal bovine serum. Cells were cultured in 5% CO₂ at 37 °C, and media were changed every 3 days. Cells were characterized for their homogeneity by immunoreactivity with anti-factor VIII antibody for BREC and with monoclonal antibody 3G5 for BRPC. Cells remained morphologically unchanged under these conditions, as confirmed by light microscopy. Only cells from passages 2 through 7 were used for the experiments.

C) Recombinant Adenoviruses-- cDNA of constitutive active Akt (CAAkt, Gag protein fused to N-terminal of wild type Akt) was constructed as in Burgering et al. (1995) *Nature* 376, 599-602. cDNA of dominant negative Akt (DNAkt, substituted Thr-308 to Ala and Ser-473 to Ala) was constructed as described in Kitamura et al. (1998) *Mol. Cell. Biol.* 18, 3708-3717. cDNA of dominant negative K-Ras (DNRas, substituted Ser-17 to Asn) was kindly provided by Dr. Takai (Osaka University). cDNA of dominant negative extracellular signal-regulated kinase (DNERk, substituted Lys-52 to Arg in ATP-binding site) was constructed as described in Her et al. (1993) *Biochem. J.* 296, 25-3. cDNA of Δ p85 was kindly provided by Dr. Kasuga (Kobe University). cDNA of PKC ζ was kindly provided by Dr. Douglas Ways (Lilly). cDNA of dominant negative PKC ζ (DNPKC ζ , substituted Lys-273 to Trp in ATP-binding site) was constructed as in Uberall et al. (1999) *J. Cell Biol.* 144, 413-425

The recombinant adenoviruses were constructed by homologous recombination between the parental virus genome and the expression cosmid cassette or shuttle vector. The adenoviruses were applied at a concentration of 1×10^8 plaque-forming units/ml, and adenoviruses with the same parental genome carrying the *lacZ* gene or enhanced green fluorescein protein gene (CLONTECH, Palo Alto, CA) were used as controls. Expression of each recombinant protein was confirmed by Western blot analysis and increased about 10-fold compared with cells infected with the control adenovirus.

D) Immunoprecipitation-- Cells were washed three times with cold phosphate-buffered saline and solubilized in 200 μ l of lysis buffer (1% Triton X-100, 50 mmol/liter HEPES, 10 mmol/liter EDTA, 10 mmol/liter sodium pyrophosphate, 100 mmol/liter sodium fluoride, 1 mmol/liter sodium orthovanadate, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, and 2 mmol/liter phenylmethylsulfonyl fluoride). After centrifugation at 12,000 rpm for 10 min, 1.0 mg of protein was subjected to immunoprecipitation. To clear the protein extract, protein A-Sepharose (20 μ l of a 50% suspension) was added to the cell lysates, after which they were incubated for 1 h, followed by centrifugation and collection of the supernatant. A specific rabbit anti-KDR or Flt1 antibody was added and rocked at 4 °C for 2 h; 20 μ l of protein A-Sepharose was then added, and the sample was rocked for another 2 h at 4 °C. For denaturation, protein A-Sepharose antigen-antibody conjugates were separated by centrifugation, washed five times, and boiled for

3 min in Laemmli sample buffer.

E) Western Blot Analysis— Immunoprecipitated proteins or 30 µg of total cell lysates were subjected to SDS-gel electrophoresis and electrotransferred to nitrocellulose membrane (Bio-Rad). The membrane was soaked in blocking buffer (phosphate-buffered saline containing 0.1% Tween 20 and 5% bovine serum albumin) for 1 h at room temperature and incubated with primary antibody overnight at 4 °C followed by incubation with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech). Visualization was performed using the enhanced chemiluminescence detection system (ECL, Amersham Pharmacia Biotech) per the manufacturer's instructions.

F) PI3-Kinase Assay— PI3-kinase activities were measured by the *in vitro* phosphorylation of PI as in Xia et al. (1996) J. Clin. Invest. 98, 2018-2026. Cells were lysed in ice-cold lysis buffer containing 50 mM HEPES, pH 7.5, 137 mM NaCl, 1 mM MgCl₂, 1 mM CaCl₂, 2 mM Na₃VO₄, 10 mM NaF, 2 mM EDTA, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 5 µg/ml leupeptin, and 1 µg/ml pepstatin. Insoluble material was removed by centrifugation at 15,000 × g for 10 min at 4 °C. PI3-kinase was immunoprecipitated from aliquots of the supernatant with antiphosphotyrosine antibodies. After successive washings, the pellets were resuspended in 50 µl of 10 mM Tris, pH 7.5, 100 mM NaCl, and 1 mM EDTA. 10 µl of 100 mM MgCl₂ and 10 µl of PI (2 µg/µl) sonicated in 10 mM Tris, pH 7.5, with 1 mM EGTA was added to each pellet. The PI3-kinase reaction was initiated by the addition of 5 µl of 0.5 mM ATP containing 30 µCi of [γ -³²P]ATP. After 10 min at room temperature with constant shaking, the reaction was stopped by the addition of 20 µl of 8 N HCl and 160 µl of chloroform/methanol (1:1). The samples were centrifuged, and the organic phase was removed and applied to silica gel TLC plates developing in CHCl₃/CH₃OH/H₂O/NH₄OH (60:47:11:2). The radioactivity in spots was quantified by PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

G) Amplification of Human CTGF cDNA Using Reverse Transcriptase-Polymerase Chain Reaction (PCR)— cDNA templates for PCR were synthesized by reverse transcriptase (First Strand cDNA Synthesis Kit, Amersham Pharmacia Biotech) from human fibroblast

according to the method recommended by the manufacturer. A standard PCR was performed (PCR optimizer kit, Invitrogen, Carlsbad, CA) using 5'-AGGGCCTCTTGACTTCG-3' (sense primer) and 5'-TCATGCCATGTCTCCGTACATC-3' (antisense primer). The PCR products were then subcloned into a vector (pCRII, Invitrogen) and sequenced in their entirety, and comparison with the published human sequences revealed complete sequence identity. This cDNA probe was used for hybridization.

H) Northern Blot Analysis-- Total RNA was isolated using acid-guanidinium thiocyanate, and Northern blot analysis was performed. Total RNA (20 µg) was electrophoresed through 1% formaldehyde-agarose gels and then transferred to a nylon membrane. ³²P-Labeled cDNA probes were generated by use of labeling kits (Megaprime DNA labeling systems, Amersham Pharmacia Biotech). After ultraviolet cross-linking using a UV cross-linker (Stratagene, La Jolla, CA), blots were pre-hybridized, hybridized, and washed in 0.5× SSC, 5% SDS at 65 °C with 4 changes over 1 h. All signals were analyzed using a PhosphorImager, and lane loading differences were normalized.

I) Analysis of CTGF mRNA Half-life-- CTGF mRNA half-life experiments were carried out using BREC and BRPC. The cells were exposed to vehicle or VEGF (25 ng/ml) for the indicated periods prior to mRNA stability measurements. Transcription was inhibited by the addition of actinomycin D (5 µg/ml). For inhibition of protein synthesis, cells were treated with cycloheximide (10 µg/ml) for the times indicated.

J) Statistical Analysis-- Determinations were performed in triplicate, and all experiments were repeated at least three times. Results are expressed as the mean ± S.D., unless otherwise indicated. Statistical analysis employed Student's *t* test or analysis of variance to compare quantitative data populations with normal distributions and equal variance. Data were analyzed using the Mann-Whitney rank sum test or the Kruskal-Wallis test for populations with non-normal distributions or unequal variance. A *p* value of <0.05 was considered statistically significant.

All patents and references cited herein are hereby incorporated by reference in their

WO 02/07747

PCT/US01/22347

entirety.

We claim:

1. A method of decreasing fibrosis in a tissue of a subject, comprising:
 - identifying a subject in need of decreased fibrosis; and
 - administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
2. The method of claim 1, wherein the agent decreases the level or activity of VEGF or a VEGF receptor (VEGFR).
3. The method of claim 2, wherein the VEGFR is KDR, Flt1, Flt4 or neuropilin.
4. The method of claim 2, wherein the agent is selected from the group of: a VEGF binding or VEGF receptor (VEGFR) binding protein that inhibits VEGF binding to VEGFR; an antibody to VEGF or VEGFR that inhibits VEGF or VEGFR activity; a mutated VEGF or VEGFR or fragment thereof that inhibits VEGF signaling; a VEGF or VEGFR nucleic acid molecule that inhibits expression of VEGF or VEGFR; and a small molecule that inhibits transcription or activity of VEGF or VEGFR.
5. The method of claim 1, wherein the agent decreases the level or activity of AKT.
6. The method of claim 5, wherein the agent is selected from the group of: an AKT binding protein that inhibits AKT activity; an antibody to AKT that inhibits AKT activity; a mutated AKT or fragment thereof that inhibits AKT activity; an AKT nucleic acid molecule that inhibits expression of AKT; and a small molecule that inhibits transcription or activity of AKT.
7. The method of claim 1, wherein the agent decreases the level or activity of PI3 kinase.
8. The method of claim 7, wherein the agent is selected from the group of: a PI3 kinase binding protein that inhibits PI3 kinase activity; an antibody to PI3 kinase that inhibits PI3 kinase

activity; a mutated PI3 kinase or fragment thereof that inhibits PI3 kinase activity; a PI3 kinase nucleic acid molecule that inhibits expression of PI3 kinase; and a small molecule that inhibits transcription or activity of PI3 kinase.

9. The method of claim 7, wherein the agent is LY294002.
10. The method of claim 7, wherein the agent is wortmannin.
11. The method of claim 1, wherein the subject has a fibrosis related disorder.
12. The method of claim 1, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, or retinal tissue.
13. A method of decreasing angiogenesis in a tissue of a subject, comprising:
identifying a subject in need of decreased angiogenesis; and
administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
14. The method of claim 13, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, retinal tissue, or cancerous or tumor tissue.
15. The method of claim 13, wherein the agent is selected from the group of:
 - a) an agent that inhibits VEGF activity;
 - b) an agent that inhibits VEGFR signaling;
 - c) an agent that inhibits PI3 kinase activity;
 - d) an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that inhibits AKT activity; and
 - f) an agent that inhibits ERK activity.

16. The method of claim 15, wherein the VEGFR is KDR or Flt1.
17. A method of increasing fibrosis in a subject, comprising:
 - identifying a subject in need of increased fibrosis; and
 - administering to the subject an agent that induces a component of the VEGF signal transduction pathway, wherein the agent increases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
18. The method of claim 17, wherein the agent is selected from the group of:
 - a) an agent that decreases a PKC activity;
 - b) an agent that increases VEGF activity;
 - c) an agent that increases VEGFR signaling;
 - d) an agent that increases VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that increases PI3 kinase activity; and
 - f) an agent that increases AKT activity.
19. The method of claim 17, wherein the agent is VEGF or placental growth factor (PIGF)
20. The method of claim 17, wherein the agent is a transition metal ion.
21. The method of claim 18, wherein the VEGFR is KDR or Flt1.
22. A method of screening for a compound that decreases fibrosis or angiogenesis, comprising:
 - providing a cell, tissue, or subject;
 - contacting the cell, tissue, or subject with a test compound; and
 - determining whether the test compound inhibits a component of the VEGF signaling pathway.
23. The method of claim 22, further comprising contacting the cell, tissue, or subject with VEGF.

24. The method of claim 22, further comprising assaying the cell, tissue or subject for a CTGF activity.

25. The method of claim 22, wherein the cell is an endothelial cell

26. The method of claim 22, wherein the cell is a bovine retinal endothelial cell (BREC) or bovine retinal pericyte (BRPC).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: A61K 45/06 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).


(71) Applicants and
(72) Inventors: SIEMEISTER, Gerhard [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). HABEREY, Martin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). THIERAUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10 Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of

15 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an

20 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

25

30 The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1 5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during 10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce 15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also 20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and 25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was 30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurstonen et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in

5 mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of

10 endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed.

15 Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies

20 (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60,

25 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al.,

30 Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led

5 to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., *J. Clin. Invest.* 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., *Cancer Res.* 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., *Br. J. Cancer* 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., *Cancer Res.* 56, 1615-1620, 1996), as well as elevated expression of Flt4

15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., *Cancer Res.* 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., *Am. J. Pathol.* 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high

20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2

25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., *Science* 284, 1994-1998, 1999; Holash et al., *Oncogene* 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing

30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., *J. Clin. Invest.* 103, 159-165, 1999; Lin et al. *Proc. Natl. Acad. Sci. USA* 95, 8829-8834, 1998; Siemeister et al., *Cancer Res.* 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. 10 Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological 10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.

Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,
(b) compounds which inhibit ligand binding to receptors,
(c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
(d) compounds which inhibit or activate expression of a ligand or of a receptor of
the VEGF or Tie receptor system,
(e) delivery systems, such as antibodies, ligands, high-affinity binding
oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of
VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
(f) delivery systems, such as antibodies, ligands, high-affinity binding
oligonucleotides or oligopeptides, or liposomes, which are targeted to the
endothelium and induce necrosis or apoptosis.

30


A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. Assoc. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: 5 ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Assoc. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is 10 prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin 15 A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas 20 (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), Nature 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 25 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described. 30 Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

5 10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

15



20

I,


in which

r has the meaning of 0 to 2,
n has the meaning of 0 to 2;

25

R₃ und R₄ a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II;




5

wherein the binding is via the two terminal C- atoms, and
m has the meaning of 0 to 4; or

10

c) together form a bridge of partial formula III



15

wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T₁ and T₄;

G

20

has the meaning of C₁ - C₆ - alkyl, C₂ - C₆ - alkylene or C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene or C₃ - C₆ - alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂, -CH₂-S-CH₂, -CH₂-NH-CH₂, oxa (-O-), thia (-S-) or imino (-NH-),

A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
X has the meaning of imino, oxa or thia;
5 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if 15 more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.


20 A preferred salt is the salt of an organic acid, especially a succinate.

These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25 Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example
anthranyl acid derivatives of general formula IV

30


11



in which

A has the meaning of group $=NR^2$,5 W has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,Z has the meaning of the group $=NR^{10}$ or $=N-, -N(R^{10})-$ $(CH_2)_q-$, branched or unbranched C₁₋₆-Alkyl or is the group


10



15


or A, Z and R¹ together form the group

20



	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
5	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/or R _a and/or R _b together with R _c and/or R _d or R _c together with R _e and/or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
15	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
20	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy,
25	R ⁴ , R ⁵ , R ⁶ and R ⁷	independently from each other have the meaning of hydrogen, halogen or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or


C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R^5 and R^6 together form the group



5 R^8 , R^9 and R^{10} independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V





15 V,
in which
 R^1 has the meaning of group





20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,



in which R^8 is -CH₃, fluoro, chloro or -CF₃


5

in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

R²

has the meaning of pyridyl or the group



10

and

R³ has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10 b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59. Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims 30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate. Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred 15 pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical 20 compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

25 The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, 30 transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with

5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and

10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor

25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thromboc microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 **Example 1**

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector 15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	- []	+
Group 4: A375v/sTie2	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

10 This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

15

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in

5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of

10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its

15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of 5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional 10 interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing 10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons 15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of

5 approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex

10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly

15 shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
10 coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the
20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx. 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a 5 volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF 10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.
The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to

5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of

10 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its

15 perpendicular.

Table 6

	mode of treatment	
treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducting L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the

5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).
The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of

15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-

30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in 5 Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine 10 kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 25 5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 30 6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

- 20 a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 25 e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 30 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target 10 cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to 15 the endothelium and induce necrosis or apoptosis.


12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20 13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

25 14. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

30 15. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one small molecule of genaral formula I

41




in which

5 r has the meaning of 0 to 2,
 n has the meaning of 0 to 2;

 R_3 und R_4

10 a) each independently from each other have the
 meaning of lower alkyl,
 b) together form a bridge of general partial formula
 II,




15

wherein the binding is via the two terminal C- atoms,
 and

m has the meaning of 0 to 4; or
 c) together form a bridge of partial formula III

20



wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the binning is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa (-O-), thia (-S-) or imino (-NH-),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

 R₁ and R₂ independently from each other have the meaning of H or lower alkyl,

 X has the meaning of imino, oxa or thia;


20 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

 Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
wherein one or more N-atoms carry an oxygen atom,
or a salt thereof,

and/or a compound of general formula IV


5



in which


A has the meaning of group $=NR^2$,
 10 W has the meaning of oxygen, sulfur, two hydrogen atoms
or the group $=NR^8$,
 Z has the meaning of the group $=NR^{10}$ or $=N-, -N(R^{10})-$
 $(CH_2)_q$, branched or unbranched C₁₋₆-Alkyl or is the
group

15



or A, Z and R¹ together form the group

20




	m, n and o	has the meaning of 0 – 3,
5	q	has the meaning of 1 – 6,
	$\text{R}_a, \text{R}_b, \text{R}_c, \text{R}_d, \text{R}_e, \text{R}_f$	independently from each other have the meaning of hydrogen, C_{1-4} alkyl or the group $=\text{NR}^{10}$, and/ or R_a and/ or R_b together with R_c and or R_d or R_c together with R_e and/ or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,
10	X	has the meaning of group $=\text{NR}^9$ or $=\text{N}-$,
	Y	has the meaning of group $-(\text{CH}_2)_p$,
	p	has the meaning of integer 1-4,
15	R^1	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C_{1-6} -alkyl, or C_{1-6} -alkyl or C_{1-6} -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R^2	has the meaning of hydrogen or C_{1-6} -alkyl, or form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R_1 ,
	R^3	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally
25		

substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

R⁴, R⁵, R⁶ and R⁷

independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R⁵ and R⁶ together form the group




R⁸, R⁹ and R¹⁰

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl,
as well as their isomers and salts,

and/ or a compound of general formula V

15




V,

20

in which


R¹ has the meaning of group

46




in which R⁵ is chloro, bromo or the group -OCH₃,

5



in which R⁷ is -CH₃ or chloro,



in which R^8 is -CH₃, fluoro, chloro or -CF₃


5

in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

 R^2

has the meaning of pyridyl or the group



10

and

 R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as
15 compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium
20 hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-
10 42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the
production of a medicament for the treatment of tumors, cancers, psoriasis,
arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye
diseases, such as diabetic retinopathy, neovascular glaucoma, kidney
diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation
rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver,
mesangial cell proliferative diseases, arteriosclerosis, damage of nerve
tissues, suppression of the ascites formation in patients and suppression of
VEGF oedemas.




Fig. 1




Fig. 2




Fig. 3






Fig. 4

**Fig. 5****Fig. 6**

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

15 <140>

<141>

<160> 59

20 <210> 1
<211> 1835
<212> DNA
<213> Human

25 <400> 1

tttacagtt ttcctttct tcagagtttta ttttgaattt tcatttttgg ataaccaagc 60
agctcttaa gaagaatgca cagaagagtc attctggcac ttttgatag tacataagat 120
tttctttttt ttttttaat ttttttaat agtcacattc agtcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttataa cgtaaaccgt 240
tatacaaaca gccaaaaaaac cataatggtg ccacagggat 240
taacgtgtc tctagtctat cttcgctaaa cagaacccac ggagcaggga agggcatctc 300
agcacactgt gttgaaacgaa ggtatgtgc cccaaatggc ttacacatg ataactagag 360
aagcaaaaaga gacatccctt aataactgtt taaaatccag acttggcagc atgcagtttta 420
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt cgcattccat taaaagggtt 480
tggagttaat gggaccagga ttggaggact cttagctgtt gtcactgtca aaaaggact 540
attaaaaggc ttggatgttta agagagaca ctcagcggtt acagatttca gtacgatttc 600
tggaccgctg agaagcggaa cagatgaaca caaaggaatc cctgaagggaa gacgctgaga 660
cattaagcg acaacaaaaa aaggcaaaccc cccaaacgc 660
aagcaaaatc agacaacgaa gcagcgatgc atagcttcc aaatctttac aaccaaattt 720
gagacgtctac gtgccaaccc aagttctcaa cgacagcttc acctaaccaa agcaaaatct 780
aaaatgactc aagcgatgca aaaagtttca tctgtttcc tttgagagaa cgcataccctt 840
gtgategtta gagecatagcg acatcacgta cgggttttta acatggat tattgtata 900
gcccggatcc cggaaaggaca ttggacacc actttcagcc gaatccgagg gagaactgag 960
tccggccaaag tcatttttttta ttccgagtaa taactttat atgtccctgg tggccgatcc 1020
gcaaaacagga atgcagtaaa cgtccacgtc cgtccacgg acctccttcg aggccgaca 1080
ctccacgaac gggtaacgcgc ttccatgaga aaggatattt tcctttctaa catttacacg 1140
tcaggggtt ctgcgatagc tcattttatg taaaacgc 1140
ttctgcagg ggcctttctt gtcttctctt tggcgagctc ctgggctgcc gttccgttcc 1200
gggggctggc tgctggctcc gagggggcat cccgactccg ggcaattttta tattccacag 1260
ggctggccag ctggccacca ctctccgac tcgacccttc tcaggggcct ctcctccgt 1320
tgtcttcggg ggtacagaccc gtggtccac attcgatacc gtggccgat cttctctgtt 1380
ggtaacacgag ctgcgtgtt gccgtgttctt ctgggctcg aggtctttc tgctgggtct 1440
cttggacggg cgggttagttc tgctgcagag acaaagcat tctggtcgtc tcctccgtca 1500
atttgggtt attcatatct acggcagat ccaaactggc tcccctttcc ttccgggctg 1560
55 cagctctttg gagaatcaat gtatgaatgt ctaacctgac atcattactt ccgttccttc 1620
gagacgaacc acgccccgggg gtgcggaaagc ggct 1680
1740
1800

60 <210> 2
<211> 581
<212> DNA
<213> Human

<400> 2

5 gttctagatt gttttattca gtaatttagct cttaaagaccc ctggggcctg tgctaccagg 60
 acactaacaa cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
 tcaacttact tcctgtggcc cattagggaa gtggtgacct cggggagctat ttgcctgttg 180
 agtgcacaca cctggaaaca tactgcttc atttttcat ccacatcagt gagaaatgag 240
 tggcccgta gcaagatata actatgcaat catgcaacaa agctgcctaa taacattca 300
 tttattacag gactaaaagt tcattattgt ttgttaaaggaa tgaattcata acctctgcag 360
 10 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtccct tgttttctct 420
 aaatgtcaag ctttactga aaactcccg tttttcagtc actggagtgt gtgcgtatga 480
 aagaaaatct ttagcaatta gatgggagag aaggaaataa gtacttgaaa tgtaggccct 540
 cacctccccca tgacatcctc catgagccctc ctgatgttagt g

15 <210> 3
 <211> 516
 <212> DNA
 <213> Human

20 <400> 3

tagagatgtt gggtgatgac ccccgggatc tggaggcagat gaatgaagag tctctgaaag 60
 tcagccaga catgtgcata tacatcacag aggacatgtt catgtcgccg aacctgaatg 120
 25 gacactctgg gttattgtt aaagaattt ggcttccac ctcgagctt tcagaaacag 180
 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cgaaaaccaa 240
 agacctccac tgatgcacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
 tccttgcgtat tgcaggctgt tgcaggaca ctgctcagag ttacacctt ggatgtggcc 360
 atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccaagcag tgcataaca 420
 30 tccaagatgc ttttccagtc aaaagaacca gcaaataactt ttctctggat ctcactcatg 480
 atgaagtcc agagttgtt gtgttaagtc cgtctg

<210> 4
 <211> 1099
 <212> DNA
 <213> Human

<400> 4

40 cccacaacac agggggccctg aaacacgcca gcctctccctc tgggtcagc ttggcccagt 60
 cctgctcaact gatcacagc ccattgttagg tggggatgg tggggatcatgg ggcccttggc 120
 ccacggggag ttagaagaag acctggtcgg tggtaagggtc tgagaagggtg ccctgggtcg 180
 ggggtgcgtc ttggccttgc cgtgcctca tccccccggc gaggcagcga cacagcaggt 240
 45 gcaccaactc cagcagggtt agcacccagg agatgagttt aaccaccaac atgaagatga 300
 tgaagatgtt cttctccgtg gggcgagaga caaaggcgtc cacgaggtag gggcagggtg 360
 ctcgtggca cacaacaccc ggctccatgg tccagccgtt caggccacat tggccataga 420
 ggaagcctgc ctctagcaca ctctgtcaga gcacactggc gacatagggtg cccatcagt 480
 ctccggat ggcaggcga ccattttctg ccacccggat ctggccatc tgacgctcta 540
 cggccggccag cggccgttcc acctgtgggt ctttggccgg cagtgcggc agctccccct 600
 50 ctttctggcc cagccgttcc tctcgccag acaggtaat gacatggcc aggttagacca 660
 gggtggtgt gctgacgaaag aggaactgca gcaccccgta gggatgtgg gagatgggaa 720
 aggctggtc atagcagacg ttggtgccgc ctggctgggc cgtgttacac tcgaaatctg 780
 actgctgtc accccacact gactggccgg ccaggcccg gatggatg cgaaagatga 840
 55 agagcaccgt cagccagatc ttacccatgg cggtcgttcc ctccctggacc tggccagca 900
 actttccac gaaaggcccg tcacccatgg ctccccggcc tccgtcgca aggagacaga 960
 gcacgtcagt gtgtcagcat ggcatttttc tggccccc agcaacaacg ctgcaggagg 1020
 gtctggccacg cccgttctac cgcctgcctg cggggggcc caggtggagg tggggacgt 1080
 ggccggagtg acgcccccg

60 <210> 5
 <211> 1015
 <212> DNA
 <213> Human

65 <400> 5

gaggataggg agcctgggt caggagtgtt ggagacacag cgagactctg tctccaaaaa 60

	aaaaagtgtct	ttttgaaaat	gttgagggtt	aaatgtatggg	aaccaacatt	ctttggattt	120
	agtggggagc	ataatagcaa	acacccccc	ggttcgacac	tgtacagggaa	ttggacccag	180
	ttggggcaca	gccatggact	tccccccct	ggaatgtgtg	gtgeaaagt	gggcagggc	240
	ccagacccaa	gaggagaggg	ttgtccgcag	acaccccccggg	atgtcagcat	ccccgcacct	300
5	gccttctggc	ggcacctccc	gggtgtgt	ttgagtccgc	aggcatgggg	tgagagccctg	360
	gtatatgctg	ggaacacgggt	gcaggggcca	agcggttccctc	cttcaggcctt	gacttgggccc	420
	atgcacccccc	tctccccc	acacaaaacaa	gcacttccctc	agtatgtgc	cagcacagg	480
	gtcccttcag	tcctctgtt	atgcacctt	gtcctacttg	ggccctcgag	cccaggctgt	540
	gttgtaacct	ctgcgtctc	aagaccacac	cttgaagatt	ctttttccct	tttgaaggaga	600
10	atcatcattt	tttgtttatc	acttttaaga	cattttgtac	ggcacgaca	agttaaacag	660
	aatgtgttc	cctccctggg	gtctcacacg	ctcccacag	aatgcccacag	ggggcgtgca	720
	ctgggcaggc	ttctctgttag	aaccccagg	gttcggccc	agaccacagc	gtcttgcct	780
	gagcctagag	cagggagttc	cgaacttctg	cattcacaga	ccacccctcac	aattgttata	840
	acccaaaggcc	tcctgttctg	ttatttcact	taaatcaaca	tgctattttt	ttttcactca	900
15	cttctgactt	tagcctctgt	ctgagccgtg	tatccatgc	gtcatgttca	cgtgtctagtt	960
	acgtttttct	tcttacacat	gaaaataaaat	gcataagtgt	tagaagaaaa	aaaaaa	

20 <210> 6
<211> 2313
<212> DNA
<213> E

<213>

<212> DNA
<213> Human

<400> 7

5

gccaaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcgc ttttaggtat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaaatg aagaccttgc 120
tattctaaaa tcagatccctt acagatccag attcaggaa acaaatacat aggggactaa 180
ctttccctgt tcagattgt ttttcttctt tgccaccgc tatataatat gaggaaatgt 240
tgactttttaaa aagtgtttt agttttccat ttcttggata tgaaaagtaa tattttcgga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggctt gaatttggtc 360
tccttttgtt gtgtccagtg ggtaacatc

<210> 8

15

<211> 157
<212> DNA
<213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcagggaa gcaagcccac tcaaaccgtga aatttggcat gagggtatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tatttttg

25

<210> 9
<211> 561
<212> DNA
<213> Human

30

<210> 10

4

<211> 1508
<212> DNA

1400 10

6

cacaaacacg agagactcca cggtctgcct gagcaccggcc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagccctct ctgtccagat ccataaggcac ggtcagtc 120
gggtcgcggg acgatcagcg gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatact tctatccggg ccctttttgtt gatggatata tcgggttgc accccaaatct 240

gagctcaaggc cagggtgagct taaggccatg agcaaggaaat acctggggcc 350
aggtgtgagg acttgtggcaa gtgcggaaatgt aaggagtgcac cttaccccaag gcctctgcca 360
tcgactgttgc tctgtcgaccaa gcaatgcgtt tgctcgcccccc 400
acttgtgttat gctgtgtgaa aggtcttottt tattactgtttt ctaatgtatgtt tgaggacaac 480
tgtqctqaca acccatqttc ttgcqagccag tctactgtttt gtacacqatgtt gtcagccatg 540

gggtgcattt ccctttttt gccttttta tgggttacc ttccagccaa gggttgcctt 600
aaatttgcc aggggtgtta tgaccgggtt aacaggcctg gttgcgcgtg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc cccccatgga actttgaaaa accaacatag 720
catcatataat caggaatatt acagtaatga ggatttttc ttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataatcttgg cactgttaat agaaaagttgg gatagtcctt 840

8

```

gctgtttcg gtggaaatgt ttttgtccat gtgcgcgttt aactgtatgg cttgtttagaa 900
ctcagctaat ggagctcaaa gtatgagata cagaacttgg tgaccatgtt attgcataaag 960
ctaaaggacac acagacactc cttagggcaaaat tttttgttttq tqaataatgtac ttgcaaaaact 1020

```


<211> 1002
 <212> DNA
 <213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
 acagggtgtgg agaacagggtt gagtagagca acaacaacaa aagcttatgc agtcaccc 120
 10 tttggaaaatg ttaataacaa gtcctattct ctttgtccag ctgggttag cttagaggt 180
 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaacg caagttact 240
 gaagtaataa tctggggccc atcgacccccc cactaagtac ttgttcacca tggttatct 300
 taaaagtcat ttttcaactgt ttgactcaga atttggact tcagagtcaa acttcattgc 360
 ttactccaaa cccagttaa ttcccactt ttttaagtag gcttagctt gagtgatttt 420
 tggctataac cgaaatgtaa atccaccc 16 aaacaacaaa gtttgcacaa actgaaatgt 480
 15 tactgaaaac aatgggtccca tatgctccaa agacatttc ccaagataac tgccaaagag 540
 tttttgagga ggacaatgtt catttattat gttaggacct tgatatctct gcaaataaga 600
 attaatacag ctcaaatacggtt gtagtaacca agctttctg cccaggaatg aacaacatc 660
 actacgaaca tgagagtaca agagggaaact ttctataatgc atttttcat tcatacatc 720
 attcaataaa cattagccaa gctaataatgtcc caagccactg tgccaggtat taacaatata 780
 20 acaacaataaa aagacacagt ctttccttc aagggttca gtctatgttggaaatgtt 840
 attcattaaa atttttgggtt catcagaatc atgaggagct tgcataatgttggaaatgtt 900
 gcctatgttc tcagatattc tggttagtgc aggggtggaa accccaaatc aattctttt 960
 acaaacaacta aagggtattc taacacaggc ggttgtgagga cc

25 <210> 15

<211> 280
 <212> DNA
 <213> Human

30 <400> 15

cgaggtgggc caccctgtgtc tggctctgaga tttttaaatg aggattacat tattcttattt 60
 ataataattcc tattctaaatc tattttattt ttacaattaa atgtatcaaa taattcttaa 120
 35 aaacattatt agaaacaaaac tgcctataac ttataaagac taaaaaaatc accaagatga 180
 aactgttata tgactctcaa tatttaaaca tttaaaaaaa tgtagtgc tgcataatgtt 240
 caatcttaac tatttcaccc gcccggccgg ccgcctcgagg

<210> 16
 <211> 2041

40 <212> DNA
 <213> Human

<400> 16

45 ccccccgcag aactcccccc tggaaatagga tttttaaaac ctttgacaat tagaaatcc 60
 atagagggtt gcatttttta ggtaaaaata tggttgcccc tacagggttc atgcaacttc 120
 cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtagtgc 180
 atacagacac agttagtgcg aagacactaa acaaaaaactg aaaaatcta taccttgata 240
 aattttgtt ttgccttctt tagagactttaatctta gtttgcattt aaggacttgc 300
 50 attaataat ggggtatata cacaagacgt aaaggatttt taaaaacaaa gtattttttt 360
 ttacctctag catcaattttt ttataaaga atgctaaataa aattacattt ttgttcagt 420
 aaaaactgtt atagaccatt taaatgttc taccaaattt aacgcagctt aatttagggac 480
 caggtacata ttttcttctg aacatttttgc gtcagcatg tctaaccata aaagcaatg 540
 gaattttaaag aggttagattt tttttccatg atgcatttttgc ttaataatgtt tgtaagaaa 600
 55 ataaaaacaa gcactgagtg tggttcttgc aagtataagg gtcataatgaa aaataaaaga 660
 tagatatttg ttatagtctg acattttaaatc agtcatatgc tttagacgttt cgtgaccagt 720
 gcattttggc ctctctcagg atcaaaaatc ggttgcctt actgttgcataatccctcc 780
 acccccctcca ccagttggc cacatgtcc ttgtgggtcg ttgtcatcaa atccattggg 840
 ccgaaatgaa catgaagcag atgcagttgc gggggccgg gtcagcat tcaactcttgc 900
 60 ttctctaaa tataatgttttgc tataatgttc ataaatgttgc ttttttttttgc 960
 tgggtctcca ttatccaga gtcacttgc ttgttttgc ttttttttttgc 1020
 atgctgtttt ttataaaaaa gcaatgttgc ttgttttgc ttttttttttgc 1080
 ctggactgac tggaaatgttgc taaatgttgc ttttttttttgc 1140
 ttgacatttc ttatccatgc ttgttttgc ttttttttttgc 1200
 65 gtaaatgttgc ttttttttttgc ttttttttttgc 1260
 aagagtctgtt acttgcatttgc ttttttttttgc 1320

taccagagt aaccacaacg gaacttaata gatagggcac caattttgt caggaagctt 1380
 catcaaaaaactt tgaaggcttt aatttttttag caaggttctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaaagaagt aattcttcta actggcaact 1500
 cccaaaccag tggccagtga tacattgtct aaaaattttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa attcaggag agtaagaata agtatttcg gttccctccgt gatttgcata 1620
 gtttctcgat cattttgcag agaggcacag ttttcacaat aatattgggtt atcaccagta 1680
 agaatctctg gagccaaaaa aataatttag taagtcagtt actgaaggtt tggtttcacc 1740
 tcccggttcc tgaggtacat ctttataac aagaatcttg ttagattcgt tagggacaga 1800
 agtgttttca gaacagtaaa actcattagg aggactgcct atggttttt cattcacaag 1860
 10 tgagtcacag atgaaggcag ctgttggattataact actggcttt ctgaaggacc 1920
 gggtacagac gcttgcatta gaccaccat ttgtatactg ggtgatgtt ctggatctt 1980
 gacagacatg tttccaaag aagaggaagc acaaaacgc acgaaaagat ctgtaaagc 2040
 t
 15 <210> 17
 <211> 235
 <212> DNA
 <213> Human
 20 <400> 17
 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaattt aaaaatttag ccaggtgtgg cagcgaacaa ctgtagtc 120
 25 agatactcgagactgac tggaaaggat cacttgagcc caagaagttc aagttacag 180
 tggccacga tcatgtcatt acactccacg ttgggtgaca aatgagact gtcta
 <210> 18
 <211> 2732
 <212> DNA
 30 <213> Human
 <400> 18
 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 35 tcatgttcat aactacttta tatggagctt cattggacct gttaccttca ttattctgt 120
 aaatatttatac ttcttgggtga tcacattgtg caaaatgggtg aagcatttcaaa acactttgaa 180
 accagattctt acgcagggtgg aaaaacattaa gcttgggtg cttggcgctt tcgccttct 240
 gtgtcttctt ggcctcacct ggtcccttgg ttgtctttt attaatgagg agactattgt 300
 gatggcatat ctcttacta tattttatgtc ttccaggggta gttttttt tcatcttca 360
 40 ctgtcttc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggggc ctcccaactg agagtccccca cagttcagtg aaggcatcaaa ccaccagaac 480
 cagtgctcgc tatttccttg gcacacagag tctgtataaga agaatgttga atgatactgt 540
 gaaaaacaa tcagaatctt cttttatctc aggtgacatc aatagactt caacactt 600
 tcaaggtggc ataaaatctt atatattttt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttataatca tttagaggac attcactgaa caatgccagg gatacaagt 720
 ccatggatac tctaccgctt aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgcaaa gttgtggact ttgtactaag tctgaatgtt actgttttt 840
 agaaaatgtt catttcagaa tttagtgcaca acaacttacg gggcagcago aagactcaca 900
 acctcgagct cacgctacca gtcaaaacctg tgattggagg tagcagcagt gaagatgtt 960
 50 ctattgtgc agatgttca tctttatgtc acagcgacaa cccagggtg gagetccatc 1020
 acaaaaactt cgaggcacca cttatccctc acggcgactca cttttttcttgc taccaccc 1080
 agaaggaaatgtt gaagtcccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacctt acagtccccca aacagagact ctctttataac aagcatgccc aatcttagag 1200
 actctccctt tccggagagc agccctgaca tggaaaagaagc cctctctccc tccaggagga 1260
 55 gtgagaatgtt ggacattttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc agggggcaata gtgtatggta tataatcccc attaacaagg 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctgggtt acaagtctt 1440
 aatcatacag ctaaggaattt ccaaggccca catgcgagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctt aaactctgtt tgaagagatg actcttgacc tgggttctc 1560
 60 tgggtaaaaa aagatgtactg aaccttgcag ttctgtgttataaaaaa catacaaaaaa 1620
 ctttgtat acacagatgacttataacttgc aatattttgt tacaagaaaa agagatgcca 1680
 gccagggtatt ttaagattttt gctgtgtttt agagaaaattt tggacaaaacg aaaaacaaaac 1740
 tttccagcca ttttactgca gcagttgtt aactaaattt tggacaaaatgg ctgcaccatt 1800
 tttttagggcc tgcattgtat tatatacaag acgttaggctt taaaatctg tggacaaaat 1860
 ttactgtacc ttacttattcc tgacaagact tggaaaagca ggagagat tctgcattc 1920
 65 ttgcagttc actgcaaaatc ttttacattttaaaggcaagat tggaaaacatg cttaaccact 1980

ctgtgattgc tgactacttt ggcagagggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctccccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg gcaacacgtg gaggaccaag 2100
 agaacagaca caatgggacc tggggggcgtt acacagaa ggctggctga catgcccagg 2160
 5 gctccactct catctaatgt cacagccctc acaagactaa agcggactt ttcttttcc 2220
 ctggccttcc ttaattttaa gtcaagcttgc acatccctt cctcttaac taggcagggtg 2280
 tttagaatcat ttccagatataatgggggaa aggggaaacct caggcaacc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c

 10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

 15 <400> 21

 aggtgttaga tgctctttagaa aaagaaaactg catctaagct gtcagaaaatg gattttta 60
 acaatcaact aaaggaactg agagaaaacct acaacacaca gcagttagcc cttaacage 120
 tttataagat caacgtgaca agttgaagga aattgaaggaaaaatttag aactaatgtc

 20 <210> 22
 <211> 905
 <212> DNA
 <213> Human

 25 <400> 22

 tttttttttt ttctttaacc gtgtggtctt tatttcagtgc cagtttac agatacaaca 60
 30 caaatgttcc agtaggaggaa aattcaacag gaatgccaag gtccaaagcca ggctcaagaa 120
 ataaaaaggaa aggtttggag taatagataa gatgactcca atactcactc ttcttaaggg 180
 caaaggactt tttgatacag agttgtatct ttgaaacttgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatggc tttaggagcac tttaaaatattt gtgggtggaa 300
 tagggtcatt aataactatg aatataatctt tttagaagggtt accatttgc actttaaagg 360
 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 35 gggagcttggaa agagccttgg aagtttctat tacaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctttt ttaactccat ctgtccagtgtt tttacaatata aactcgcaag 540
 gtctgaccag ttcttggtaa caaacatatacata tttgtgtgtc tttgtgttata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc ttcaaaacat tggggaaacc agtagaaaaaa 660
 40 ggcagggtctc cctaattgtcc attattacat ttccatttccg aatgcagat gttaaaatgt 720
 cctgaagatg gtaaccaggc tagtgaggaa taaataccaccc accttgcctt gtccacagag 780
 aacaacagt agaaagaagg ggcaacttgc tgctgcagag acaaagttag tttttttcc 840
 ccatggattt cagtcctctc ctccagacca gtcgttattt tcctcagggg cccaggaaat 900
 gttga

 45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

 50 <400> 23

 ggctctttctt ttcctttttt ttttccaaa agtgttcttt tatttcagt aacatataattt 60
 gtataaataac tctattttat atgcacttcc acaaaagcga tataattttaa aagttttttt 120
 55 cattagaaat aaatgtataa aaataatataat gttattatag gcatttatta ctaactatata 180
 tccttcttgg aaggaacacc caaaccaata cttataaaatgtt acatgttaattt tatagttataaca 240
 tattttacta tatacatatg gaaaaatca tatttcataca gaagagctga acagacattc 300
 accaggatac gactgttggc ccagctgctg gagatggacc tgctaccctt cagcagccctc 360
 cccaccacaa gacaagtgtt ctcaatgtcc ccaaaacctgtt gggaccctgt tctacacacc 420
 tcattttgtt tccggctttt catcctcctt gtgtgattt actgattttc atgagacaca 480
 60 agttacttctt ttacatccat attcccaaaag cagggttaca tggtagggaa gaaaggaaatg 540
 tggaggtact aagctcatttgc tgctcttccctt agcttttacc agcatctaat gtcctactgc 600
 tttttttccca tttagactttaatgcactt gaaataatataatgtt gttttcccttca 660
 aaatgtatca cacaataaa gactgagatgtt gtcacaaaaaaa gggaaaggaa agccatttgc 720
 gttatttccat gttgctgagc ctttctctca ttttgcacaa ttttgcacaa ttttgcacaa 780
 65 tagaaaataat gtataaataat tctctgaaac catagcagcc ataaaacagtgc ctggtaaag 840
 atccatatttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 900

taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtatttgat 960
 aagtaccagg aaacacgggg ttaaatagtt ctaactttt ttgacaattt ctttgggtt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatggccgg ggctttata 1080
 tgctatatca ctgctcagag gttataatc ctcactaact atccatcaa atttgcact 1140
 5 ggcagttac tctgatgatt caactcctt tctatctacc cccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgcttccct 1260
 gcaccagccc ttccctactt tgccctggcc tcaaagctaa caccacttaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgtttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt ttttggtaac 1440
 10 ccttcccaca ggtcttagaa catgatgacc actcccccag ctgcccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctggct tcacttccct tgccacactcg gaagcagggct 1560
 gtccattaaat gtctcgcat tctaccatgc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccaacttca atgaccatgc ctgaaaaagt gggatagca ttgaaagatt 1680
 ccttcttctt cttacgaag taggtgtatt taattttagg tcgaaggcca ttgcccacag 1740
 15 taagaacctg gatggtaaag ggctcttga gagggtctaa gctgcgaatt ctttccaatg 1800
 cccgagagga gcccgtgtac ctcaagacaa cacccttgcataatgtct tgctctaagg 1860
 tggacaaagt gtatgcacca ttaagaatat atgtgccatc agcagcttgc atggcaagaa 1920
 agctgccatt gttcctggat cccctctgg tccgctgttt cacttcgtg ttggtggctc 1980
 20 cagtggaaat tttgtatgata tcatgatatac caggtttgc actagtaact gatccgtata 2040
 ttttttaca agtagatcca ttccccccgc aaacaccaca ttatcaaac ttcttttgg 2100
 agtctatgtatgcgatcaca ccagcttttca caca

<210> 24
 <211> 1626
 25 <212> DNA
 <213> Human

 <400> 24

 30 ggacaatttc tagaatctat agtagtatca ggatataattt tgctttaaaa tataattttgg 60
 ttattttggaa tacagacatt ggctccaaat tttcatctt gcacaatagt atgactttc 120
 actagaactt ctcacacattt gggaaactttt caaatatgag catcatatgt gtttaaggctg 180
 tatacattaaat tgctatgaga tacattgtt tctccctatg cccaaacaggt gaacaaacgt 240
 agtttttt tactgataact aaatgttggc tacctgtgat tttatgtat gcacatgtca 300
 35 gaaaaaggca agacaaaatgg cctcttgc tgaataacttc ggcaaaactta ttgggtcttc 360
 atttctgac agacaggatt tgactcaata ttttagagc ttgcgtagaa tggattacat 420
 ggtatgtatg cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtcttttat tgtaagcata tctgaattta ctttataaaatg atgggttttag 540
 aaagctttgt ctaaaaattt ggccttagaa tggtaacttc attttcgtt gccaaggggat 600
 40 agaaaaataa tatgtgtttt gttatgttta tggtaacata ttattagta ctatctatga 660
 atgtatattaa atattttca tattctgtga caagcattta taatttgcacaa caagtggagt 720
 ccatttagcc cagtggggaaa gtcttggaaac tcaggttacc cttgaaggat atgctggcag 780
 ccatctctt gatctgtgt taaaactgtaa ttatagacc agctaaatcc ctaacttggaa 840
 tctggaatgc attagttatg ccttgcattca ttcccagaat ttcaaggggca tcgtgggtt 900
 45 ggtctagtga ttgaaaacac aagaacacagag agatccagct gaaaaagagt gatccctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tttgtatcatg 1020
 aaacttagta gaggggatgt tttgtatattt atacaatattt aatacaatgtt cttacattga 1080
 taaaattctt aaagagcaaa actgcattttt atttctgtcat ccacattcca atcatatttag 1140
 aactaagata ttatctatg aagatataaa tggtgccagag agactttcat ctgtggattg 1200
 50 cgttggtttct taggggttctt agcactgtatgc cttgcacaaatg catgtatgtatgtt gtaaaaaaaa 1260
 atgattctt ctatagctaa atgaggcccccttctggggggaa gttctggatc tgcaatcaca 1320
 atgccagatg gtgtttatgg gctatttgc tttgtatgtttaa gtaagatgtt atgaagtaag 1380
 tttgttttttgc ttcatctttaatggaaacttctt gatgcattgtt cttttgtatg gataaaatattt 1440
 55 tggtgcaata tgatgtcatt caacttgcatttca ttgaaatttgcattttttgttatttatttattgtt 1500
 attataccctg tcacgcttctt agttgcttca accattttat aaccattttt gtacatattt 1560
 tacttggaaa tattttaaat ggaaattttaa ataaacattt gatagtttac ataaaaaaa 1620
 aaaaaaa

<210> 25
 <211> 1420
 <212> DNA
 <213> Human

 <400> 25
 65 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggttgtttaa tcattatgtc 60

5	ttcattgaaa tccttgctac ttcttcctt cctcaatgaa agacacgaga gacaagagcg 120 acacaagctt aagaaaaacg agcaaggaag agtatcttc ttattctcat tttctcttag 180 ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240 agtggaaaaa cttaagagt ttccacatat tagtttcat ttttgagtc aagagactgc 300 tccttgtaact gggagacact agtagtatat gtttgaatg ttactttaaa attatcttt 360 tattttataa ggcccataaa tactgtttaa actctgtttaa aagtgggcct tctatcttgg 420 atgtttcac tgccatcagc catgctgata tattagaat ggcatcccta tctacttact 480 ttaatgctta aaattataca taaaatgctt tatttggaaa acctacatga tacagtggtg 540 tcagccttgc catgtatcag ttcaacttga aatttgagac caattaaat tcaactgttt 600 agggtggaga aagaggtaact ggaaaaacatg cagatggaga tatctttat gtcaacagt 660 atccttgc tggggggaga gttactcttgg aaaggcaggc agcttaatgt gacaatgttt 720 tgtatatagt tgagaattttt acgacatctt taaaattgtt gtaattgtt aatgtccagt 780 tttgcctgtt ttgccttggaa gtttttagtat ttgtttctt ggtggacccctc tgaaaaccaa 840 accagttaccc ggggaggtt gatgtgttgc tcaggcttgg agtgtatgag tggttttgct 900 tgatattttcc tccagagatt ttgaacttta ataatttgcgt gtgtgtttt ttttttttaa 960 gtggctttgtt tttttttctt caagtaaaat ttgtacataa ttccctttat aggggcagg 1020 catgagttag ggagactgaa ggtttagttaa gactgtatcat gtgccttctt aatgtgtttc 1080 tcgacacattt ttttttcgtt aacttggaaa ttcaaaagggg acatttggttt aggttactgt 1140 acatcaatctt atgcataaaat ggcagttgtt ttcttgcgtt cactgtctaa attttgtttt 1200 tatagaaattt ttttatactg attgggttcat agatggtcag ttgttacac agactgaaca 1260 atacagcact ttggccaaaaa tgagtgttagc attttttaaa cattgtgtttaa taacacctgt 1320 tctttgttaat tgggttggttgg tgcattttgc actaccttggaa gttacagttt tcaatcttgc 1380 agtaaataaaa gtgtcccttaa acttcaaaaaa aaaaaaaaaaa
25	<210> 26 <211> 689 <212> DNA <213> Human
30	<400> 26
35	aaacaaaacaa aaaaaaaatggt agtactgttat atgttaatac tagctttca atgtgtata 60 caaacaattt tagcacatcc ttccctttac tctgtctcac ctccctttagg ttagtacttc 120 cttaaataag tgcttaacat acatatacgg aacttggaaag ctttgggttag ccttgcctta 180 ggtaatcagc ctatgttaca ctgtttccag ggtagtagttt aattactata aaccatttgc 240 caacttgc tgcaccattt atcacaccag gacagggtct ctcaacctgg ggcgtactgt 300 catttggggc cagggtattt ttcccttgcgg gggctgtccct gtacctggcc gggcggccgc 360 tcgaaggctg gtgcggccgg aggttactgaa aggaccaagg agctctgggtt gcccctcagga 420 40 attccaaatg accgaaggaa caaaatcttca gggctctggg tgggtctcc cactatttgc 480 gagggtggtcg gaggtaacgc agtcttcat tgcaggacttcc ttcccaatgtt taaaatgtt 540 tgtcaagatg ctgcattttttaa tcaggcagggtt ctacaaaggc atccccaaagca tcaaacatgt 600 ctgtgtatgaa gtaatcaatg aaacaccggaa acctccggacc accttcttgcgaa tagtgggaga 660 cacaccccaga ggcgttgcgtt tgccttgc
45	<210> 27 <211> 471 <212> DNA <213> Human
50	<400> 27
55	tcccaacccggc atgaagtttgc agattggccaa ggccttgc tctgggttca tctccttcgt 60 ccctctcgctt cattgggttgc accctgtttt gctgtcttgc ccaggacgg gcaacccttaca 120 agcccttaacc caggccccgc ccaggccac caccggactt gcaaaacccgg cacctgcctta 180 ccagccacca gctgccttaca aagacaatcg ggccccctca gtgacccctgg ccaccacaggc 240 gggtacaggc tgaacgacta cgtgtgttttcccacaggctt gcttctcccc tgggtctgt 300 tgggtgggtt cccggccgggaa ctgtcaatgg aggcagggtt tccagcacaa agtttacttc 360 tgggtcaattt ttgtatccaa ggaataatgt tgaatgcgag gaaatgtt ttagagcaca 420 ggacagaggg gggaaataaga ggaggagaaa gctcttctata cccaaagactg a
60	<210> 28 <211> 929 <212> DNA <213> Human
65	<400> 28

5 ggtgaactca gtgcattggg ccaatggtc gacacaggct ctgccagcca caaccatcct 60
 gctgctctg acggtttggc tgctgggg cttccccc actgtcattt gaggcatctt 120
 tggaaagaac aacgcgcagcc ccttgatgc accctgtcgc accaagaaca tcgcccgg 180
 gattccaccc cagccctggt acaagtttac tgcatccac atgactgtt gaggcttctt 240
 10 gccttcagt gccatctctg tggagctgtt ctacatctt gcccacgtat ggggtcg 300
 gcagttacact ttgtacggca tcctcttctt tgcttcgc accctgtcga gtgtggggc 360
 ttgcatttcc attgcactca cctacttcca gttgtctggg gaggattacc gctgggtgt 420
 gcgatctgtg ctgagtgtt gctccaccgg ccttttcatc ttctctactt cagtttcta 480
 15 ttatggccgg cgctccaaaca tgcgtgggc agtacagaca gtagagtttct tcggctactc 540
 cttaactact gtgttatgtct tcttcctcat gctgggcacc atctccctttt tttcttccct 600
 aaaggtttccatc cggtatatctt atgttaaccc caagatggac tgaggctgtt atggcagaac 660
 tattgtgtt ctctccctttt ctcatgcacc tggtaactc ttcttcttcc ttccttctg 720
 attgtactgaa ttgtgtgtatc gcatgttgc ttcttctttt tcccttctg ctttcttcc 780
 20 ccagagaggg cctggaaattt ataaatcttcc atcacataag gattatatat ttgaactttt 840
 taaggtcct ttagtttgg tccctgatttt tcttttaca attaccaaaa taaaatttt 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

 25 <210> 29
 <211> 1775
 <212> DNA
 <213> Human

 30 <400> 29
 25 gaacgtgtatc ggaactttgg gaggatgtct gagaaaatgt ccgaaggat tttggccaaac 60
 accagaaaaac gccaatgtcc taggaattcc ctcccaaaat gttcccaaa aaattactca 120
 ttgacaattt aaatttgcact tggctggcg cagccggggc ggccttcagt ccgtgtggg 180
 30 cggccgcgtg gccttctctt cgttagactc cccaaactcg ttcaactctgc gtttatccac 240
 aggataaaacg caccgtgtt acaggtagac cagaaacacc acgtcgcccc ggaagcaggc 300
 cagccgtgtt gacgtggggc tgggtatgtt gaaggccaaacg acgtcatcaa tgaagggttt 360
 gaaagccgtt taggtgttggg ctttccaggc cagatgtgc acgtactca actttgtt 420
 cacaagagc tggggcagca tgaagggaa accaaaggca tagaccctgt tgacgaagct 480
 35 gttgatatac caggagtacc agctttata ttgtatattt aggagtgaat agacacgacc 540
 cccgacacag agagggtaca gcaggatgtt caagtacttc atggcccttag tatctactc 600
 ctcggtttc ctctcagatt cgctgttactt gccaaacttca aattcggca tcaggctct 660
 ccaaaaaata gtcatcttca atgccttctt cactttccac agctcaatgg cggctccaaac 720
 40 acccgccggg accagcacca gcaggctgtt ctgtctgttcc agcaggaaca gaaagatgac 780
 cacgggtgtt aaggcagccgc agagactgtc ctgggtggac atgcccattca tgctttctt 840
 cttttccatc aaatgtatgtt catttttttggccaggaaa tcaaaagagaa gatggaaacgc 900
 tgcacaaag aagggtcaggcc ccaaggatgtt taatgtgtt tcttttttttcccttccac 960
 ctcatcagatc tctttctctt aaaacccggaa ctgtctgttcc gaggatcactt cgtctctgt 1020
 45 gtgatccatc aaggcgcaggcc gccccatgtt gaccttgcgtt taggacacgg tgaggggcag 1080
 ctcgggtgtt gaggcgttta tgaccatcag gtccttcacg cggtgtgtt gctggctgtt 1140
 gaacaggatg ggcaggtaat gcaagggtttt cccaggctgg atcatcttca tgcgttccatc 1200
 cacatggca ggcaggggg acccgtaaa gacaaatgtt tccgcattca cgttcaggcc 1260
 cagccgcgtt cggccagggtt acactgtgtt atccaggggca ctgtctgttccgc 1320
 50 ctcgtatctgc tggatgtatcacttccgtt gaggatgtt gatgttccgtt gcttggggac 1380
 catgttaggtt gtcagaggac tgaccatgtt caccctgttcc cggctgtcc acggcaggac 1440
 cccagggtgtt gggaggaaatc tggatgttccatc cggatgttccatc ttgtttctgtt 1500
 tacagaaaaatc ttaactgttcc tttccaaatgtt gggactccaca tcaaaatgtt ccacattca 1560
 55 gaccagggttccatc tggatgttccatc cggatgttccatc tggatgttccatc tggatgttccatc 1620
 ctgcagcttgc gggccggccggcc cggatgttccatc tggatgttccatc tggatgttccatc 1680
 gcggtgttagt acgtgttccatc acatgttccatc gcaaggatgttccatc accacgttccatc 1740
 gcccaccacc aaggctgttccatc aggatgttccatc gcccc

 60 <210> 30
 <211> 1546
 <212> DNA
 <213> Human

 65 <400> 30

 65 aaaataagta ggaatggggca gtgggttattt acatttacta cacctttcc atttgctaat 60
 aaggccctgc caggctggggc gggattgttcc cctgcctgtt tctggatgttccatc 120

acaccatcta cgggcacccat ggaactgtttt caagtgacca ttctttttct tctgcccagt 180
 atttgcagca gtaacagcac aggtgtttt gaggcagctt ataatttcaact tttttttact 240
 acaacaaaac catctataac aacacccaaac acagaatcat tacagaaaaa ttttttcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcacaatg aattacttaa aatgtctctg 360
 5 atgtcaacag ctacttttt aacaagttttt gatgaaggat tgaaaggccac aaccactgt 420
 gtcaggaaga atgactccat catttcaaaac gtaacagttt caagtgttac acttccaaat 480
 gctgtttca cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattttttttttt 540
 acagaatatac caggtagtgt tctacaacca gatgcacac cttctaaaac tttttttttttt 600
 acttcaatc caggtagtgt tccagaaaaac accttccatg tttttttttttt tttttttttttt 660
 ggtggaaaaa atgcaagcac ttcagcaacc agccggctt attttttttttt tttttttttttt 720
 gtggttattt cttttttttt aataacactt tttttttttt ttctttttttt tttttttttttt 780
 atgtcttggg aggccacacca gaaaatggaa atgatcaacc tttttttttttt tttttttttttt 840
 aaagagagcg tgaagtttcc tttttttttt acaatttctc atgatctgg tttttttttttt 900
 15 gcacaaggaa aaaccaagaa ctgacagttt gaggattttt tttttttttt tttttttttttt 960
 tacgtttatc tttttttttt tttttttttt tttttttttt tttttttttttt tttttttttttt 1020
 aatcccgact tccatccatc tttttttttt tttttttttt tttttttttt tttttttttttt 1080
 tccagctgac atgcaatatac tttttttttt tttttttttt tttttttttt tttttttttttt 1140
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttttt 1200
 gaggagaattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttttt 1260
 actttccatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttttt 1320
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttttt 1380
 gcaaggaaaaa gttgcacgtt tttttttttt tttttttttt tttttttttt tttttttttttt 1440
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttttt 1500
 aatactctaa aaatactata acatgtactgt gaaaatggca aaaaaaa
 25 <210> 31
 <211> 750
 <212> DNA
 <213> Human
 30 <400> 31
 cacttggca cccccatttt cttttttttt gggaaatctgg agggccaaaaa aggtgtgt 60
 35 aagggaagtgc cttctgtatgg cccaaaaacc ttcttccaaa cttttttttt tttttttttt 120
 atagcaatatg gatcctttt ggcctccccc ggagcatgcc tttttttttt tttttttttt 180
 cccactaaag cagaacgtt cggatatttc tttttttttt tttttttttt tttttttttt 240
 aacagccccc ccctaatttttggg aaaaatgcagt cttttttttt tttttttttt tttttttttt 300
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360
 40 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420
 gtggcaagggc aattttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 actggccatc ggtttttttt aaaaaggatc tttttttttt tttttttttt tttttttttt 600
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660
 45 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720
 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780
 <210> 32
 <211> 1620
 <212> DNA
 <213> Human
 50 <400> 32
 gcaattttttt cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 60
 55 gtgcagccat tcataagaac cttttttttt tttttttttt tttttttttt tttttttttt 120
 ctgagggtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 180
 atctgtgcac acttctgtatc tttttttttt tttttttttt tttttttttt tttttttttt 240
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 300
 60 atgtttctggg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 360
 aaaaaaaact tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420
 cgctggcatt tggactcaat gaaaaggcca tttttttttt tttttttttt tttttttttt 480
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 gggtagctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600
 atttggatgtt cacaggaaac cttttttttt tttttttttt tttttttttt tttttttttt 660
 65 tggagttgtt cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 780

10 <210> 34
<211> 6011
<212> DNA
<213> Human

<400> 34

15

20	acggggcgcc	ggacgaccgg	cacatcttat	cctccacgcc	ccactcgcac	tcggagcggg	60
	accggcccccgg	actccccctc	ggggccggca	ctcgaggagt	gaggagagag	gcccggccggcc	120
	cgggttgagc	cgagcgcagc	accccccggg	ccccgcgcca	gaagtttggt	tgaaccgggc	180
	tgcggggaga	aacttttttc	tttttcccc	ctctccggg	agagtctctg	gaggaggagg	240
	ggaactcccc	cgggccaaagg	ctcgggct	gggggtcgcg	eggccgcaga	agggggcgggg	300
	tccggcccg	aggggaggcg	ccccgggga	cccgagaggg	gggtgaggac	cgccgggctgc	360
	tggtgcggcg	gccccagcgt	gtcccccgcg	caggggaggc	gcccggccgc	tccggggcccg	420
25	gctgcgagga	ggagggcgccg	gccccgcagg	aggatgtact	tggtgcggg	ggacagggggg	480
	ttggccggct	gcccccaect	cctgtctcg	ctgctgggg	tgtctgtct	gccccgcggc	540
	tccggcaccc	ggggcgttgg	ctgcctgccc	tgtacgaggt	ccaagtgcga	ggagcccagg	600
	aaccggccgg	ggagcatctgt	cgagggcgct	tgcggctgt	gctacacgtg	cgccaggccag	660
	ggaacgaga	gctcgccgg	cacccctggg	atttacggaa	cctgcgacccg	ggggctgctg	720
30	tgtgtcatcc	gccccccct	caatggcgac	tccttcacccg	agtacgaagc	ggcgcttgc	780
	gaagatgaga	actggactga	tgaccaactg	tttggtttt	aaccatgca	tgaaaacatt	840
	attgtctggct	gcaatataat	caatggaaa	tgtgaatgt	acaccattcg	aacctgcagc	900
	aatccctttg	agtttccaaag	tcaggatatg	tgccttcag	ctttaaagag	aattgaagaa	960
	gagaagccag	attgctccaa	ggcccgctgt	gaagtccagt	tctctccacg	ttgtctgtaa	1020
35	gattctgttc	tgatcgaggg	ttatgtctct	cctggggagt	gtgtccctt	accaggccgc	1080
	tgcgtgtgca	accccgccagg	ctgtctgcgc	aaagtctgc	agccggaaa	cctgaacata	1140
	ctagtgtcaa	aaggcctcagg	gaagccggga	gagtgtgt	acctctatga	gtgcaaaccata	1200
	gttttcggcg	tggactgcag	gactgtggaa	tgcctactt	ttcagcagac	cgctgttccc	1260
	ccggacagct	atgaaaactca	agtcaacta	actgcagat	gttgcgtac	tttgcacaa	1320
40	agatgcgagt	gtctctctgg	ttatgtgg	ttccccgtgt	gtgagggtgg	atccactccc	1380
	cgcatactct	ctcggtggca	tggacaccc	ggaaagtgt	gtgatgtctt	tgaatgtgtt	1440
	aatgatacaa	agccagccctg	cgtatccaac	aatgtggaa	attatgatgg	agacatgttt	1500
	cgaatggaca	actgtcggtt	ctgtcgatgc	caagggggcg	ttgccatctg	cttcaccggcc	1560
	cagtgtgttg	agataaaactg	cgagaggtac	tacgtccccg	aaggagagt	ctgcccagt	1620
45	tgtgaagatc	cagtgtatcc	ttttaataat	cccgctgg	gtatgc	tggcctgatc	1680
	cttgccca	gagaccgggt	gccccggac	gactgcacat	tctgc	cgtcaacgg	1740
	gaacgcact	gcgttgcac	cgtctgcgg	cacacgtca	caaaacgt	gaaagtgcct	1800
	ggggaggttt	gcccctgtgt	cgaagaacca	accatcatca	cagtgtatcc	acctgtcatgt	1860
	ggggaggttat	caaactgcac	tctgacacgg	aaacccagg	ttaatgttt	caaacgcgtat	1920
50	cacaatgggt	gtcgacactg	tcagtgcata	aaacccagg	aactatgttc	agaacgtaaa	1980
	caaggctgc	ccttgcactg	tccttcgg	ttccttactg	atgccccaaa	ctgtgagatc	2040
	tgtgatgtcc	gccccaggcc	caagaagtgc	agacccataa	tctgtgacaa	gtattgtcca	2100
	cttggattgc	tgaagaataa	gcacggctgt	gacatctgtc	gtgtaa	atgtccagag	2160
	ctctcatgca	gtaaagatctg	ccccctgggt	ttccagca	acagtac	ctgttcttac	2220
55	tgcaagtgc	gagaggcctc	tgcttcagct	ggggccacca	tcctgtcg	cacttgttctc	2280
	accgtggatg	gtcatcatca	aaaaatgag	gagagct	acgatgggt	ccggaaatgc	2340
	tactgtctca	atggacggga	aatgtgtcc	ctgatcacct	gccccgt	tgcctgtggc	2400
	aacccca	ttcacccctgg	acagtgtc	ccatcatgt	cagatgact	tgtgtgcag	2460
	aagccagagc	tcagtactcc	ctccatttgc	cacccccctg	gaggaga	cttggggaa	2520
60	ggagaaacgt	ggaacatgt	ctctgtact	cagtgcac	gcccacgg	acgggtgt	2580
	tgtgagacag	agggtgtccc	acgctgtc	tcggaa	cctca	ccaggattcc	2640
	tgtgtccac	agtgtacaga	tcaaccttt	ccgccttct	tgtccc	taacagcgta	2700
	cctaattact	gcaaaaatga	tgaagggat	atattcctgg	cagtgagtc	ctggaaagcct	2760
	gacgtttgt	ccagctgcat	ctgcattgt	agcgtta	gctgttctc	tgagtctc	2820
65	ccttctgtat	cctgtaaaag	acctgtcttg	agaaaaggcc	agtgtgtcc	ctactgcata	2880
	aaagacacaa	ttccaaagaa	ggtgtgtgc	cacttcagtg	ggaaggccta	tgccgacgag	2940

5 gaggcgtggg accttgacag ctgcaccac tgcactgtcc tgcagggcca gaccctctgc 3000
 tcgaccgtca gtcgcccccc tctgcccgtgt gttgagccca tcaacgtgga aggaagtgc 3060
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
 aaccatcgag gagagggtga cctggaggtt cccctgtggc ccacgcctag tggaaatgtat 3180
 10 atcgccatc tccttagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
 caccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgcctctcta ttataatagc attccttattc atcaatcaga agaaacagtg gataccactg 3360
 ctttgcgtgt atcgaacacc aactaagct tcttcctaa ataatcagct agtacgtgt 3420
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgt aagaattgca 3480
 15 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttctt accaaacagt gtgaagaaag gcaacttaga tgaggtttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaaact agaattttgtg cacttgctt gtggattgt 3660
 ttggattgtg actttagtgc cagcgctaa accttactgg gatgggtct gtctacagca 3720
 atgtcagaa caagcattc cactttcctt caagataact gaccaagtgt tttcttagaa 3780
 20 ccaaagtttt taaaagggtct aagatataattt tgccgttaag atagctgtat agatattttgg 3840
 ggtggggaca gtgagtttg atggggaaag ggggtggagg cagttcagtg gcccagaggt 3900
 tggtcagctt ggctcggggaa gaaacctgtt aacataaaaag cttttttttt ctattgtctt gaagactgca ctgtgtgt 3960
 25 gcagggaaaca aaaaaggccct tgcgaccac cttggcataac cttttttttt cttttttttt 4020
 agcacaatcag aacccttttga cagccatccc aggtcttaaag cttttttttt cttttttttt 4080
 cagtcacaac tgcgttaggc agtgaggaaag ccagagaaat gctttttttt tcttccaagg 4140
 aagccgggtt ttaaggatata atacaggatatactttttgtt gctttttttt tcttccaagg 4200
 caataatca gccaggtttccatc agcagagtca gcacatgaaac aagatcttaaag tcattttttt 4260
 atgtgagcac tggagctttt ttttttttca acgtgacagg aagaggaggg agaggggtgac 4320
 30 gaacaccagg cattttccagg ggcttatattt cactgtttgtt gtttgcctt tttttttt 4380
 ttgttgggtt ttcatagttt ttgttgaagc tctagcttaa gactgtttgg ggattttttt tttttttt 4440
 35 gactgtttgg ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 4500
 atttttaatttgc tatattatttc aaggcacctttt gtttgcattttt aaaaaaaatg atgcctttttt 4560
 aaacttttagc aattatagga gtattttatgt aactatctta ttttttttccattttt aaaaaaaatg atgcctttttt 4620
 40 tttgtgtcata ttttttttccattttt atatatatataatcatatata ttttttttccattttt aaaaaaaatg atgcctttttt 4680
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 4740
 45 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 4800
 ctttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 4860
 50 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 4920
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 4980
 atttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5040
 55 atttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5100
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5160
 60 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5220
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5280
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5340
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5400
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5460
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5520
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5580
 tacattacaa aatagatgg acatcagctt gattgtata aattttttttt aaaaaaaatg atgcctttttt 5640
 catttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5700
 caatttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5760
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5820
 ttttttttccattttt ttttttttccattttt atactgattttt aattttttttt aaaaaaaatg atgcctttttt 5880
 cacttggagt gcatcatgt tctacagttt gttttttttt ttttttttccattttt aaaaaaaatg atgcctttttt 5940
 65 gaatttatctg caacttggattt ctggcagga aataaaacattt ttttttttccattttt aaaaaaaatg atgcctttttt 6000
 aaaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

65 mylvagdrg1 agcghllvsl lgllllpars gtralvclpc deskceeprn rpgsivqgvc 60
 gccytcasqg nescggtf1 ygtcdrglrc virpplngds lteyeagvce denwtdqll 120
 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdm1 lsalkrieee kpdcskarce 180
 vqfsprcped svliegyapp geccpplsrc vcnpagclr1 vcpqgnlnil vskasgkpg 240

ccdlyeckpv fgvdcrtrvec ptvqqtacpp dsyetqvrlt adgcctlptr ceclsglcgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnn veyydgmfr mdncrfcrcq 360
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 5 ctfccvngc rhcavatvcgq tctnpvkpg eccpvceep t itvdppacg elsnctltrk 480
 dcincfkrdh ngrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkcr 540
 piicdkycpl gllknkhgcd icrckkcpel scskicplgf qgdshgclic kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsc cpqctdqpf pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
 viscfsescp svscerpvlr kgqccpvcik dtipkkvvch fsgkayadee rwldlscthc 840
 ycllqgqtcls tvscpplpvcv epinvegscc pmcpemvypc ptinpiektn hrgevdlevp 900
 lwptpsendi vhlpdmghl qvdyrdnrlh psedssldsi asvvppiic lsiiiaflfi 960
 nqkkwipll cwyrtptkps slnnqlvsd ckkgrtrqvqvd ssqmlriae pdarfsgfys 1020
 15 mqkqnhlgad nfyqtv
 <210> 35
 <211> 716
 <212> DNA
 20 <213> Human

 <400> 35
 25 gcagtacctg gagtgccctg cagggggaaa gcbaaccggg ccctgaagtc cggggcagtc 60
 accccgggct cctggggccgc tctggggc tggggcttag cagcgatctt gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctctcc cccggacgcc gcagtttct 180
 ggaggcttaga gaaggcatga agagtggctt ccacctgctg gccgactgag aaaagaattt 240
 30 ccagaactcg gtcctatttt acagatttag aaactatggt tcaagaagag aggacggggc 300
 ttgagggaaat ctcctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggctttt taaggctcta aatgtcaggg tctccatcc cctgatgcct gacttgtaca 420
 gtcagtgtgg agtagacggt ttctccacc cagggttgac tcagggggat gatctgggtc 480
 35 ccattctgtt ctaagaccc caaacaaggg tttttcage tccaggatct ggagcttca 540
 tctggtagt gtcgttaact ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600
 ccccatcca cctaacaggg tggccacagg gattacttag ggttaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaaa aaaaaaa

 <210> 36
 <211> 395
 40 <212> DNA
 <213> Human

 <400> 36
 45 ccaatacttc attttcatt ggtggagaag attgttagact tctaagcatt ttccaaataa 60
 aaaagctatg atttgcattt caactttaa acattgcatt tcctttgcca tttactacat 120
 tctccaaaaa aaccttggaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattggaatc ctttagccta tgcattttt cttaacttt gcactttcac 240
 50 gcccagtaaa accaaagtca gggtaaccaa tgcattttt caaaaatgtta aaaccctaat 300
 tgcaagtccct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

 <210> 37
 <211> 134
 55 <212> DNA
 <213> Human

 <400> 37
 60 ccctcgagcg gcccgggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccctataaa gtcgcctggc ttcagcaac aggcctatca acaccatggt gagtcctccat 120
 aaggacacc gtgt

 <210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

5 aagcctgtt tcatggggga ggtggggcg cttggggcc actggcgcc gaggtagagg 60
 cagtggcgct ttagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
 gggaaagatgt ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatattgg tggggccagca atccctcagac gcctcaactt ggacaaatga ggaaactgag 240
 gcttggtcaa gttacgaaac ttgtccaaaa tcacacaact tggtaaaggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaaagttt aggagaaaga 360
 aggtatgtt tggccatgg gccagtcgtc cacatcgtg gcagacatgtt gaagaaggcg 420
 ttccacccgg aaaaatgttagc ttccggta agtacattgg ccatgttagaa gttgatgaat 480
 caagggaaat gcacatctgtt gaagatgtt taaaatggaa gaaagctgaa aggaagtct 540
 15 tcaaggcctt ctttggaaaa actggaaaga aagcgtttaa agcagtttctt gttggctaa 600
 gcagatggac tcagagggtt tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

25 ctttttgttt gggttttcca atgttagatgt ctcagtggaa tggcagata tactttgttc 60
 cttatatgtt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
 gcctccatc taatctttt gatactctt gatatcttgc ctgaggagcg atttctgaat 180
 tagccagtgt tggatccact ttctgtttagg aattgttataa gaataaccc ttcttttcag 240
 acctgcttagt tgagacatct tggggaaatgtt agtagggaaaa tagacatggt gtggaaaaac 300
 agcaaaatgtt gaacattaaa aagactcatt caagtatgtt tataaaggc atggaaattc 360
 30 tggccctttt agccaaaatgtt gaagaaaaaaa ttctgcttagt cagtattcac tggatgtt 420
 tttttgtttt ttacacgaa tggaaaaatgtt atgtgttataa ggtatgttattttaatcagct 480
 aacagtactt ccagagatgtt tgatcagcac caattccat agttagtaatgtt attttaaatgtt 540
 taagaaatac tactacattt aacattataa agtagatgtt tggacataac tggaaaaatttgc 600
 atgtttgtttt caatagaaat ttgtttccac ttgtatgtt aacaaaatattt tcggaaac

35 <210> 40
 <211> 1328
 <212> DNA
 <213> Human

40 <400> 40

acaattttaa aataactagc aattaatcac agcatatcag gaaaaagtac acagttagtt 60
 45 ctggtagtt tttgttaggtt cattatggttt agggtcgtt agatgtatata aagaacctac 120
 ctatcatgtt gtatgtatca ctcattccat ttcatgttgc catgcatact cggcatcat 180
 gctaataatgtt atccctttaa gcactctcaa gggaaacaaaa gggcctttt tttttataaa 240
 ggtaaaaaaa attccccaaa tattttgcac tgaatgttacc aaagggttgaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgc aagtataataa gaaaatagct tctaaatcaa 360
 50 acttccttca cagtggcggtg ttcatttcaactt caaggactgtt gcattcaatgtt aataattttt 420
 taagattcac tataatgttgc agttagatgtt gcattttttt aaaaatgcatt agactctttt 480
 ccattccatca aataattttac aggtggcat ttaatacaga tatttcgtat ttccccact 540
 gctttttattt tgatcagcat cattaaaacac taagcttgc taaaaggccca tcagcaacac 600
 tgaagagatc agtagtaaga attccattttt ccctcatcgtt tgaagacacc acaaatttggaa 660
 actcagaact atatttctaa gcctgcattt tcactgtatgc ataattttctt tagtaatattt 720
 55 aagagacagt ttttctatgg catctccaaa actgcatttgc atcacttagtc ttacttctgc 780
 ttaattttat gagaaggat ttttcattttt aattgtttt gggattactc cacatcttgc 840
 tttattttttt gactaatcgtt atttcaataa ggttgcgtt aaattggggg tctaaaaatgc 900
 attggattgtt catatggttt gcccgcattt ggggtttacag gcattggccca aacattttttt 960
 60 tgatgttattt atttataatgc agccatggaa ttcttattt gggatgttgc caatcttaca 1020
 ttttatagat gtcataatgc tatttttcat aggtgtttt gaaatgttgc ttgttcttctt 1080
 gtgatgttgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1140
 ctgcacttgc ggcacgtact gcagtgttgc gaaatgttgc gaaaatgggt tataaaaaatc 1200
 tggaaaataaag aaagggaaatgc ttcttgcattt tcttataattt gaaatggggaa aaaaatggggaa 1260
 ttttaactgg aatgttgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1320
 65 tggaaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human

5 <400> 41

aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgttagg caggtAACAT 60
 tgagctctt tcaaaaaagg agagctttc ttcaagatTTA ggaagtggta gttatgggtgg 120
 10 taaccccccgg ctatcagtcc ggatgggtgc cacccttcct gctgttaggat ggaaggcagcc 180
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catgggaagg 240
 tggttctacc ttcttcctggc ttctttttt aaaggcctgg ctggggagct ttcttttggg 300
 tggtttttc tcttccaacc aacagaaaaag actgttcttc aaagggtggag ggtcttcatg 360
 aaacacagct gccaggagcc caggcACAGG gctggggggcc ttggaaaaagg agggcacaca 420
 15 ggaggaggga ggagctggta gggagatgt ggttttaccc aagggtctcgA aacaaggagg 480
 gcagaatagg cagaggcctc tccgtccccag gcccattttt gacagatggc gggacggaaa 540
 tgcaatagac cagcctgcaa gaaagacatg tgTTTTGATG acaggcagtg tggccgggtg 600
 gaacaagcac aggccttggA atccaatggA ctgaatcaga accctaggcc ttccatctgt 660
 cagccgggtg acctgggtca attttaccc tttttttttt cagttttttt atctgtcaaaa 720
 20 tgaggctgt gatacctgtt ttgaagggtt gctgagaaaaa ttAAAGATAA gggtatccaa 780
 aatagttctac ggccatACCA cccttAAACGT gcttaatctc gtaagctaa cagggtcagg 840
 cctggtagt acctggatgg ggagagatg gaaaacatac ctggcccgag ttggagttgg 900
 acttgttctt aacagtacg tggcacacag aaggcactca gtaaatactt gttgaataaaa 960
 tgaagttagcg atttgggtgtg aaaaaaaaa

25 <210> 42
 <211> 956
 <212> DNA
 <213> Human

30 <400> 42

cggacgggtgg ggcggacgcg tgggtgcagg agcagggcgg ctggcactg ccccaaccaa 60
 ggaaggagcc cctgagtccg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
 35 ttgcctgtct aaaggcttaa ctaagactcc cggggggggc tggccctgtg cagaccttac 180
 tcaggggatg ttacctgtt gtcgggaag ggagggggaaag gggccggggg gggggcacgg 240
 cagggcgttg gcagccacac gcaggggggc agggcggccca gggacccaaa gcaggatgac 300
 cacccaccc caccgcactg cttcccccga atgcattttgg aacccaaatgc taaactgagc 360
 tcgcagcccc cgcgcctcc ctccgcctcc catcccgctt agcgtctgg acagatggac 420
 40 gcaggccctg tccagcccc agtgcgtcg ttccgggtccc cacagactgc cccagccaa 480
 gagattgtg gaaaccaatg caggccagggt gggcggacaa aaggccagg tgccggcttg 540
 ggggaacccg tgctccgggg actggactgt ttttttcaca catgttgcc gcagcggtgg 600
 gaaggaaagg cagatgtaaa tgatgtttt gtttacaggg tatattttt ataccttcaa 660
 tgaattaattt cagatgtttt acgcaaggaa ggacttaccc agtattactg ctgtgtgt 720
 45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgtg accccatcac 780
 tcgcaggacc aagggggggg ggactgtcggtt ctcacggcccc gctgtgtccct ccctccctc 840
 cttcccttgg gcagaatgaa ttcgatgtgtt attctgtggc cgccatctgc gcagggtgg 900
 ggtattctgt catttacaca cgtcggttca attaaaaaagc gaattatact ccaaaaa

50 <210> 43
 <211> 536
 <212> DNA
 <213> Human

55 <400> 43

aaataaaacac ttccataaca ttttgttttca gaagtctatt aatgcatacc cacttttttc 60
 cccttagttt ctaaatgtt aagagagggg aaaaaaggct caggatagtt ttccacctcac 120
 agtgttagct gtctttttt ttacttctgg aatagagac tccatttaggg ttttgacatt 180
 60 ttgggaaccc agttttacca ttgtgtcagt aaaaacatTTA gatagttga gagcatatga 240
 tctaaataaa gacatttggaa gggtagttt gaattctaa agtaggttaat agccaaatag 300
 cattctcatc ctttaacaga caaaaactta ttgtcaaaa gaatttagaaa aggtgaaaat 360
 attttttcca gatgaaactt gtgcacttc caattgacta atgaaataca aggagacaga 420
 ctgaaaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480
 65 agggtggttt ccccgccacc tggacctgga caggtaggg tccgtgttta accagt

5 <210> 44
 <211> 1630
 <212> DNA
 <213> Human
 10 <400> 44

 ggggaggggac gagtatgaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
 gctccctggg caccaagtcc caggcaggag cagctttt ccatcccttc ccagacaagc 120
 tctatttta tcacaatgac ctttagagag gtctccagg ccagctcaag gtgtcccact 180
 atccccctcg gagggaagag gcagaaaaat tctcccggg tccctgtcat gctacttct 240
 ccatcccagt tcagactgtc caggacatct tatctgcagg cataagagaa ttataaggca 300
 gtgatttccc ttaggcccag gacttggcc tccagctcat ctgtcccttc tggcccat 360
 catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 gactttaactt gattgcccctc agttttgggt tgctttatgg gaaagagaga gacaaagagt 480
 tacttggttac gggaaatatg aaaagcatgg caggatgca tagaggat tctagcagg 540
 gacaggattg gtcagatga cccctgggg ctctcccaatg cttgaaatgc attccatgtat 600
 attaggaagt cgggggtggg tgggtgtgt gggctagttt ggttgaatt taggggcccga 660
 20 ttagcttggg tacgtgagca ggggtttaag tttaggtctg cctgtatttc tggccctt 720
 gaaaatgtcc ccttcttcag tgcagaccc cagtcggcgt gtcctatcg tgccagaaaa 780
 agtagacatt atccctcccccc atccctcccccc cagtgcaact tgacctagct atgccttgtt 840
 gcccagtgac ctggggggagc ctggctgca gcccctcaact gttccctaaa ccttgggtggc 900
 tttgttccatg gtcccccagg gggactcagg gaggaaatgt gctgagttct gtatgttcca 960
 gagttggctg gtagagccctt cttaggggttcc agaaatattag cttagggatc agctgggggt 1020
 25 atggaaatggg ctgaggatca aacgtatgtt ggtgaaagaa taccaggatg ttgtctaaagg 1080
 tgaggggacag tttgggtttt ggacttacca ggggtatgtt agatctggaa cccccaatgt 1140
 aggtggggagg gaggtaaggat cagatggaa gatagggttgg gacagggttgg ctttggatgt 1200
 aaagagtgac ctttagagggc tccttggcc tcaggaatgc tcctgctgt gtgaagatga 1260
 30 gaagggtctc ttactcaattt aatgtatgtt gactatattt accaaagccc ctacctgtg 1320
 ctgggtccct ttagccatcag gagactgggg ctaaggccc ctcccaggaa agggacacca 1380
 tcaggccctct ggctgaggca gtagcataga ggatccattt ctacctgcat ttcccaggg 1440
 actagcagga ggcagccctt agaaaccggc agttcccaag ccagcgtctg gctgttctt 1500
 cattgtcaat gcccctctcc caacctctcc tctaaccac tagagattgc ctgtgtctg 1560
 cctcttgcctt ctgttagaat gcagctctgg ccctcaataa atgcttctgtt cattcatctg 1620
 35 caaaaaaaaaa

 <210> 45
 <211> 169
 <212> DNA
 40 <213> Human

 <400> 45

 45 tttttgtttt ttagttttttt attttttgtat taacaggagt cttattacac ataggctctga 60
 taaaactgggtt ttagatctt cagttgttccat ccagtgtctgc ataactatgtt aacgtatgaa 120
 gggaaaacgacgacaaaaaacgaaaaaatgtt gcttggaaaga ctttagttga

 <210> 46
 <211> 769
 <212> DNA
 50 <213> Human

 <400> 46

 55 tgcagggtcat atttactatc ggcaataaaaaa ggaagcaaaag cagttttttt cagccgggtgg 60
 atttgcgtt ttcactttttt ataaatgtctt acataaaaaatg tcataatttcc aaattttaaaa 120
 acataactcc agttcttacc atgagaacacg catgggttccat acgaaggatc ttcttggggaa 180
 aaacaaaaaaac aaaaacaaaaaa aacaatgtatc tttttttttt atcacaatcaa atgagatata 240
 aagggtgtact aggcaatctt agagatctgg caacttattt tttttttttt tttttttttt tttttttttt 300
 60 ccaagagacgtt ttagatgtttt aatgtatgtt tttttttttt tttttttttt tttttttttt tttttttttt 360
 cttccatataa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 420
 ggcctggccctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 480
 catggccatgtt aatgtatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 540
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 600
 tttagatgtatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 660
 cctggccctttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 720

ccatcaagag ggctatggga gccaagtcaa cacggggat tgaggcta at tcacctgaac 420
 tggaaaacag cgcccagctt ctcaccgca ggcacgcgtc tttctttt ttttcctcga 480
 gacggagtc cgctgtttg cccaggctgg agtcagttg cacggctcg gctactgca 540
 agtccacct cctggatca taccatttc ctgcttcage cttccgatg gctggacta 600
 5 tagtgccaa ccaactacgc tagctaattt tttttgtat ttttagtaga gacagggtt 660
 caccgttta gccaggatgg tctcgctctg actttgtat ccggccgcg cggcctccca 720
 aagtgtggg attacaggcg tgagccacca caccggccc cggcacgtat ctttaagga 780
 atgacaccag ttccctggctt ctgaccaaag aaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtggtggcag caacactgca gctgtctcg gatgctgtc ggggtgcctc 900
 10 cgaggcgggt gtgaacacgc cactcaaca tgacgaggcg cctggctcg gtgtgcctc 960
 acttcagtgg tgcaccccttga tggtggaaac cagcccttgg ggcaggaaac cagctcagag 1020
 aggtccatcca gctcagtc tggcaggcgc cagttatc cagccataat gtgttaaag 1080
 aaaaacacg ttctgcaaga aactctcttca cccgctcggtt agactggggc tccttgctt 1140
 15 ggatgagctt cactcaacgt ggagatgggt gtggactgtt ccctgaaaag cgggccttgc 1200
 agggcaagt gagggtcctca ggtccataac ccagtggccc tctgaaaagg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagttc ctttggaggc ttggctgag agaagagtga 1320
 gcaggggagct gggaaatggtc caggcaggga aggagactga agtgattcgg ggctaattgcc 1380
 tcagatcgat gtatttctct ccctggcttc ccggagccctt ctgtcaccc ctgctgcct 1440
 gcaggaggcc catcttttctt gggagcttac ctgacttaac ttcaactaca agttcgctct 1500
 20 tacgagaccg ggggttagcgt gatctcctgc ttccctgagc gcctgcacgg cag

 <210> 49
 <211> 921
 <212> DNA
 25 <213> Human

 <400> 49

 30 ctgtggtccc agtactactgag gaggtgtggg cgggaggatt gtttggcccc aggagttgga 60
 tggcgtatg agccaaagatc gcacccatttc cttccactct gggccacgg gcaataccct 120
 gtctcagaaa acaaacaaca aaaagcagaa acgtgttgc ggtcggttta cggggaaaacc 180
 gctgtcaga acacttggctt actccatccc cagatcgtt gacccggaa tgagggttgg 240
 tccccggagg cttttctcca agctgttgc accagaccgg ccatggaaac cctggccaca 300
 gaagccctcc gggggagttagtcc agcagacgtt gaccgtgtt gttgtgtc tgggtggag 360
 35 ggagggtggg gagggtgttgc ggggtgtgtgt tgcccccggg ggtgttcatg ggcaagcatg 420
 tgcgtgcctg tgggtgtgc tgcccttccc ctgcagccgtt cgggtgtatc tccctccagc 480
 cccttcgcca cttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagact 540
 ccacggtttt ttaagggggg accttccctt ggacccgggg gtctcgccgt atctcatgac 600
 40 cagggtctaa atgacccgac atgcatttccatc tggcttgc tgaccaactt ccctgtcccc 660
 gtcccgctgtt cctggccccc tggcgttca cgtgtatgtc tgctcctgtc attgtgttgc 720
 actgtgttgc acataccattt ggttggaaat ttcatgttac atgtgtgtca tggaaaat 780
 ttcaaataaa atggacttgc tttagaaagc caaaaagctg tgggtcctt ccagcacggc 840
 tactttgacc tcttgcctac aacccttcc ttgggtccgc ggctggtagc ttgttcaact 900
 tcagatgggtt gggggcgggtt g

 45 <210> 50
 <211> 338
 <212> DNA
 <213> Human
 50 <400> 50

 atgatctatc tagatgcctt accgtaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattaccctt atttctctac ttcccatgtt agccaaactt tccaaaattt 120
 55 catgttctgtt cttcatttcc tcatgttcaa cccaccctgtt cttagctacc acccctcgtt 180
 aacgacctag cctgggtaga aacaatgtc agcatgatac cataactcaat gatcctcgtt 240
 cactgttgc attgtcatca ttccatggcc ttactttccc ttcctgcatttgcatttgcata 300
 gtaagaaaact ttcttctgtt aattcttgggtt tcttcttgg

 60 <210> 51
 <211> 1191
 <212> DNA
 <213> Human
 65 <400> 51

5	cttagcaaggca ggttaaacgag ctttgtaaaaaa acacacacacat accaacaacat ccggggatgg 60 ctgtgtgttgc ctagagcaga ggctgattaa acactcagtg tggggctct ctgtgccact 120 cctggaaaat aatgaatttg gtaaggaaca gttataaga aaatgtgcct tgcttaactgt 180 gcacattaca acaaaagagct ggcagctcct gaaggaaaag ggcttgc gctccgttc 240 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cctcccccagc acaccctcat 300 tacatgtgtc tgcgtggct gatctgtca tctgtcgga gacgcctctg acaagtcggg 360 aatttctcta ttctccact ggtgaaaga ggggatttc cccgtctct cttctgtcac 420 ccccgctct cttcccccagg aggtccttg atttatggta gctttggact tgcttcccg 480 tctgactgtc cttgactct aagaatggaa aagctgagct ggtgaaggaa agactccagg 540 ccatcacaga taaaagaaaa atacaggaag aatctcaca gaagcgtctg aaaatagagg 600 aagacaact aaagcaccag catttgaaga aaaaggcctt gaggggagaaa tggttctag 660 atggaatcag cagcgaaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatctt 780 aaaaagctga actgcaaatc tcaacgaagg aagaggccat tttaaagaaa ctaaaagtcaa 840 ttgagccgac aacagaagac attataagat ctgtgaaagt gggaaagagaa gaaagagcag 900 aagagtcaat tgaggacatc tatgtataa tccctgaccc tccaaagtcc tacataccctt 960 ctaggttaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat agggaaagctt 1020 tatatgccat gggaaattaaa gttgaaaaag acttgaagac tggagaaaat agatgtctgt 1080 cttccaatac ctctggccat cagatgactt taaaaggtaa aggagaaaaa gtttaagatg 1140 atggcaaaaa gtccagtgta ttcatgtaa tgctaatc aagtggagg t
10	<210> 52
15	<211> 1200
20	<212> DNA
25	<213> Human
	<400> 52
30	aacaggggact ctcactctat caaccccaagg ctggagtcgg gtgcgcac cctggctccc 60 tgcaacacctc gcctccagg ctcaagcaac tctctgtct cagtcgtct agtagctggg 120 atacaggca cacacccacca tgcccagcca atttttgcat tttttttaga gacagggttt 180 cgccctctgt ccaggccggc atcatatact taaaatcatg cccagatgac tttatatact 240 aatacaat atcaggttgg tttaaaata attgtttttt tattttttt gcatttttgc 300 accaacacctt atgtatgtt aataatgtttt atactgttgc ttaacaacag tatgacaatt 360 ttggctttttt ctttgttataa ttttgttattt ttttttttta ttgtgtggc tttttttttt 420 ttctcagtgt tttcaattcc tccttgggtt aatccatgga tgcaaaaccc acagatatga 480 agggctggct atatatgtat tgatgattgtt cctattatat tagttataaa gtgtcattta 540 atatgtatgtt aaagttatgg tacagtggaa agagttagttt aaaaataaa catttggacc 600 tttcaagaaa ggttagcttgg tgaatgtttt cacccatcaaa ctatgtccca gtcagggtc 660 40 tgctactaat tagctataat ctttgcacaa attacatcac cttttagtct cagttgcctc 720 accttggaaaat tgaaaacttggatcttc taaggtaact tccagccctg tcattctata 780 actctgttat gctgagaaat aatttccat tttgttaact gtatgtatgtca aactgaaaat 840 gattattaaa gttggaaaaaa gccaatttgc tctcttagaa agctcaacta aatttggaaa 900 gaataatctt ttcaattttt taagaattta aatatttttta agggtttgac ctatattttt 960 45 agagatgggg tctcactctg tcacccagac tggagttacag tggcacaatc atagctact 1020 gtgcctcaa attcatgggc tcaagtgtatc ctcctgcctc tgcctccaga gtagctgcga 1080 ctatggccat gtgccaccac gcctggctaa cattttgtattt gacatttttta tttttttgtt 1140 tttataatctt tttttttttt ttttttttacaa aatcagaaaat acttatttttgc 1200
50	<210> 53
	<211> 989
	<212> DNA
	<213> Human
55	<400> 53
60	aagccaccac tcaaaaacttc ctatacattt tcacagcaga gacaagtggaa cattttttttt 60 tatgcctttc ttcctatgtt tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120 gattcaatta gtccttgggc tggtcactg tgcaggagtc caggaggcct ctacaaatgc 180 agagtgtactt ttaccacacca taaaacccatag atacatgc aaagcaggac cttccctcc 240 ggaatgtgcc atttcagatg cacagcaccc atgcaggaaaa gctggaaattt tttttttttt 300 cgactgtgtat agagggtctt acatgtacat tttttttttt tttttttttt tttttttttt 360 gtttcgtttt tgcccaggctt gagggtcaatg cgtgtatctca ctcactgcaaa ttccacccctt 420 aggttcaaggc attctctgtc tcagcctctt agtagctggg ttacaggcac tgccaccatg 480 ccggctaaattt ttgtatTTTTt gttagatgtt gttttttttt tttttttttt tttttttttt 540 cccaacacctca gtgtatgtcc acctcagctt cttttttttt tttttttttt tttttttttt 600
65	

5 cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaaag agggaaaataat 660
 ttctctgaag tacttgataa aattttccaaa caaaacacat gtccacttca ctgataaaaa 720
 attaccgcg gtttgcacc taagagtatg acaacagcaa taaaaagtaa ttccaaagag 780
 ttaagatttc ttccatcttca ttccatctg aatgactgca gcaatagtt tttttttt 900
 tttttttt ttgcgagatg gaatctcgct ctgcgcccc gcgggagtgc actggcgaa 960
 gcccggctca ccgcaatctc tgccacccg

 10 <210> 54
 <211> 250
 <212> DNA
 <213> Human

 15 <400> 54
 catttccccca ttggtcctga ttttgaagat ttagttaaag aggctgttaag tcaggttcga 60
 gcaaggctt ctacaagaag tagggatca agtccctcac atgggttatt aaaaacttaggt 120
 agtgggtggag tagtggaaaaaa gaaatctgag caacttcata acgttaactgc ctttcaggga 180
 aaagggcatt ctttaggaac tgcattctggt aaccacaccc ttgatccaag agcttagggaa 240
 20 acttcagttg

 <210> 55
 <211> 2270
 <212> DNA
 <213> Human

 25 <400> 55
 gccccccca gcaaggccccg cgcctccgc gccttctccg cggggaccc gaggcggaaa 60
 gggccggcg cgcggccagcc ctcgcctccc tggccacccg gcacaccggc cggccacccc 120
 gaccccgctg cgcacggccgt gtcggctgca caccagcttgg ttgggttctt cgtggccgg 180
 ctcgccccgg gtcactcttg cgcggccacaa tgagctcccg catggccagg ggcgtcgct 240
 tagtcgtcac ctttctccac ttgaccagggc tggcgctctt caccctggccc gtcgtctgcc 300
 30 actgccccct ggaggccccc aagtgcgcgc cggggagtcgg gctggccgg gacggctgcg 360
 gtcgtgttaa ggtctggcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
 accacaccaa ggggctggaa tgcaacttcg ggcggcaagtc caccgtctg aaggggatct 480
 35 gcaagactca gtcagaggc agacccctgtg aatataactc cagaatctac aaaaacgggg 540
 aaagtttcca gcccaactgt aaacatcgtt gacatgttat tgatggcc gttggctgc 600
 ttccctgtgt tcccaagaa ctatctctcc ccaacttggg ctgtcccaac cctccggctgg 660
 40 tcaaaggatc cgggcagtgc tgcggagggt ggggtctgtt cggaggatgt atcaaggacc 720
 ccatgggaga ccaggaggc ctccttggca aggagctggg attcgtatcc tccggagggtgg 780
 agtttgcagag aaaaatggaa ttgttgcag ttggaaaagg cagctactg aagccgtcc 840
 ctgttttgg aatggggccct cgcattctat acaaccctttt acaaggccag aatgttattt 900
 ttcaaaacaac ttcatggcc cagtgctcaa agacctgtgg aactgttac tccacacccgag 960
 45 ttaccaatga caacccttag tgcggccctt tgaaagaaaac cgggattttt gagggtgcggc 1020
 ctgtggaca gcaactgtac agcagccctga aaaagggcaaa gaaatgcgc aagaccaaga 1080
 aatccccca accagtcaagg ttacttacg ctggatgttt gatgttgcag aataccggc 1140
 ccaagactgt cgggtccctgc gtggacggcc gatgtgcac gcccacgtg accaggactg 1200
 tgaagatgcg gttccgtgc gaagatgggg agacattttt caagaaacgtc atgtatgtcc 1260
 50 agtcctgtca atgcacactac aactggccgc atgcacatgtt agcagcggtt cccttctaca 1320
 ggtgtttcaaa tgacattcac aaatttttaggg actaaatgtt acctgggtt ccaggccaca 1380
 cctagacaaa caagggggaa gagtgcaga atcagaatca tggggaaaat ggggggggggt 1440
 ggtgtgggtg atggggactca ttgttagaaaag gaaggcttgc tcatttttgc ggagcattaa 1500
 55 ggtatttcga aactgcacaa ggtgtgggtt cggatggaca ctaatgcgc caccatttgg 1560
 gaataactttt cttcatagta ttggagcaca ttgttactgt tcatttttgc gcttggggag 1620
 ttgtgtactt tctgttttctt gtttggaaat tattttctaa gcatattttc tctaggctt 1680
 tttcccttttgc ggggtctaca gtcgtaaaag agataataag attatgttgc cagttttaaag 1740
 cttttattcg tcctttgaca aaagtaaatgg ggagggcatt ccattccctc ctgaagggggg 1800
 60 acactccatg agtgtctgtt agggcagct atctgcactt taaaactgc taaaatgc 1860
 ggtgtttttaa gactgaatgt ttatatttttcaaaaatgttgc ttttggggag ggagggggaaa 1920
 tgaataactg gaataatttgc taaatgttgc taatgttata ttcatcttataa gatattttttt 1980
 tatggattttaa accatattaaat aaagaaatatttttgc ttcgtggaaa agatattttttt 2040
 tatttttaga ggtgtccaa agtatttttgc aacaaccttgc ctcacgtactt caatttttca 2100
 aacaggactt atggggatc agcgttgcattaaatggggatc aaaaatggggaaa atgttgc 2160
 ttatccatgc agtagagaaa agtcttgc tataaaatggggaaa ttctgttgc tttttttttt 2220
 aacacqacat tttatgttgc acaatatttttgc ttctgttgc aaaaatggggaaa atgttgc 2280

5 <210> 56
 <211> 1636
 <212> DNA
 <213> Human
 10 <400> 56

 cttgaatgaa gctgacacca agaaccgcgg gaagagctt ggcggaaagc agggaaaggaa 60
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagccgg ggcggccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ctttctcccc agatggctcc 180
 tggtttgcctt ggtctcaagg acactgcac tgcataactga tcccctggcc gttggaggag 240
 cagttcatcc ctaaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaagg 300
 cggggcagcc caaaagagaa gacgctggac tgggtcaga ttgtctgggg gctggccctc 360
 15 agcccggtgc cttcccccacc cagcaggaag ctctggcac gcccaccaccc ccaagtgc 420
 gatgtctctt gcctggttct tgcatacgga ctcacatcg ggcagatcaa gatctggag 480
 gtgcagacag ggctccctgt tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
 agcttcacac ccagtggcag tttgattttgc tgcctccgcgt cacgggataa gactcttcgc 600
 atctgggacc tgaataaaaca cggtaaacag attcaagtgt tattcgggca cctgcagtgg 660
 20 gtttactgt gttccatctc cccagactgc agcatgtgtgt gtcctgcagc tggagagaag 720
 tcggttttc tatggagcat gaggtctac acgttattc ggaagctaga gggccatcaa 780
 agcagtgttgc tctcttgc tttctccccc gactctgccc tgcttgcac ggcttcttac 840
 gataccatg tgattatgtt ggacccttac accggcggaaa ggctgaggc actccaccac 900
 25 acccagggtt accccgcattt ggtacacatg gacgtccaca ttatcacttactt gagatctgtg 960
 tgcttctctc cagaaggctt gtaccttgc acgggtggcag atgacagact cctcaggatc 1020
 tggggccctgg aactgaaaac tcccatgtca tttgtcttca tgaccaatgg gctttgtgc 1080
 acattttttc cacatggtgg agtcatgtcc acaggggacaa gagatggcga cgtccagttc 1140
 tggacagctc cttagggtccct gtccttcaactt aaggactttt gccggaaagc ccttogaagt 1200
 30 ttccatcaaacc cttaccatgtt ccttagactgc ccaatccccca agaaaaatgaa agatgtcc 1260
 acatcacatggtt aactggatgg aacaccatctt cttgtcttca ttttgtacag ggtttatcg 1320
 cctgtcaaaag ggatgtctg gaataatggg ccaatcatct ggtttgcac tgaaatagca 1380
 tttttttggg attgtgatataat gaatgttagca aaaccagattt ccagtgtaca taaaagaatt 1440
 tttttgtctt taaaatagata caaatgtcta tcaacttttca tcaagttgttacttatattg 1500
 aagacaattt gatacataat aaaaattat gacaatgtcc tggggaaaaaaa aaaatgtaga 1560
 35 aagatggtga agggtgggat ggtatgaggag cgtggtgacg gggggctgca gcggggttggg 1620
 gaccctgtgc tgcattt

 <210> 57
 <211> 460
 40 <212> DNA
 <213> Human
 <400> 57

 45 ccatgtgtgt atgagagaga gagagattgg gaggggaggagg gagctcaacta ggcgcataatgt 60
 gcctccagggg ggctgcagat gtgtctgagg gtgagccctgg tgaaaagagaa gacaaaagaa 120
 tggaaatgagc taaaaggcggcc gcctgggggg ggaggccggc cccatttgc tgcagcagg 180
 ggcaggagcc cagcaaggaa gcctccatcc ccaggactct ggaggagact gggccatcc 240
 50 atggcccgac agccccccttccatcacactt cctgtccacgc ctaatttgc tggggactgg 300
 aactggggat gggaaatgtcac atagaatgttgc actggcaggag ctggggactgg aacccaaacca 360
 gcctcttgc tccatcaat ggaatgttagt agactccacg caggtgggtt 420
 ccggactcga attcgtaatc atggtcatacg ctgtttccctg

 <210> 58
 55 <211> 1049
 <212> DNA
 <213> Human
 <400> 58
 60 atctgtatcaa gaataacctgc cttggtcaact ctggggatgt ttctgtccac ttgttcacat 60
 tgaggaccaa gatatccttttttacatgggg cacttgcgttgc gtcataacaca gacacccatcc 120
 tgacgacatg ctggctcaca ttttgcgttgc tgcagaatgtt cccctccca gcctggacta 180
 cagcagcact ttccctgggg ggtgcgttgc cgtttccac agggcctgg gcaactctgaa 240
 65 gtcgtgtct gttgcaggatgg taccgtggct ctgcattccctt caggcataa aggtcttttgc 300
 ggatctacaa ttttgcgttgc tgcatttgc tgcataactttt actgtttgtat 360

aaaatgtaaa cttcacctag ttcatcttct ccaaattccca agatgtgacc ggaaaatgg 420
ccttacagg acccaactgt gcccacacag agtggttttt cttgccactg ctttgtcaca 480
ggactttgtt ggagagtttag gaaattccca ttacatctc caaacacgtt gcttccatac 540
5 aatcttctg actggcagcc ccggtatatac aatccaccaa ccaaaggacc attactgaat 600
ggcttgaatt cttaaaagtga tggctcaatt tcataatctt tcccctttat tatctgtaga 660
attctggctg atgatctgtt tttccattt gactctgaac acagtatcgt taaatttgatg 720
tttatatcg tggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
aacacttcgg gggctgggtt ggtgctgtt aagtgtgggt tgctcccttgg tatggataa 840
10 ggcacgttgc acatgtctgt gtccacatcc agccgttagca ctgagcctgtt gaaatcaatt 900
aaccatcca ttcttccat atcatccagt gtaatcatcc catcaccaag aatgtatgtac 960
aaaaaccctt cagggccaaa gagcagttgc cttccagat gcttctgtt gagttctgca 1020
acttcaagaa agactctggc tggctcaaa

15 <210> 59
<211> 747
<212> DNA
<213> Human

20 <400> 59
ttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaacgtc 60
ccttaattta caaaggctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
cttaaatata atgtatcata ccaacccaag taaaaccaagt aaaaaaaaaata ttcatataaa 180
25 gttgttcaca cgttaggtcct agattaccag cttctgtca aaaaaaggaa atgaagaaaa 240
atagattttat taacttagtat tggaaactaa ctttgcctt ggcttaaaac ctccctcactg 300
ctcgctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgtatga 360
aaagaagccc ctggcacaaa agattccagt gcccctgaag aggctccctt cttccctgtgg 420
gctctccatg aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
30 ccctcgggca ggcaacggca gtggactcat ctccgtgtt gctgttagatg ctaacactgg 540
ccaaatccat gccacaccta ctggttaccc ttggagggtt tttctccaga cagaagcccc 600
ttgaaggctta gtagggcag gatcagatg acacccgtgtt tggtctcgaa gggctccaca 660
gcccagtacg acatgtttgc agaagtagta tctctggact tctgcctcca gtcgacccgc 720
cgcaattta ttagtaatacg cggccgc

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.